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Abstract
The genetic and molecular underpinnings of neonicotinoid (NNI) resistance are currently
unknown in honeybees.  Honeybees within the same colony exposed to clothianidin at the dose required
to kill half of the population (LD50) exhibited different survival rates based on their genetics.  The goal of
my research was to explore transcriptomic differences in the brain, Malpighian tubules and ventriculus
between non-resistant and resistant patrilines that had been exposed orally to a field realistic dose (4.6
ppb) of clothianidin for 2 hours.  Transcriptomes were compared after 24 hours of exposure using RNA
sequencing and the analysis revealed an upregulation in proteolysis and catabolic processes in the
Malpighian tubules of non-resistant bees.  This change in expression is likely a result of lack of
neonicotinoid metabolism by the CYP9 enzymes. Finally, I compared the transcriptome of the Malpighian
tubules, ventriculus and the brain and discovered that the majority of detoxification enzymes were highly
upregulated in the Malpighian tubules.  These findings shed light on the consequences of NNIs exposure
and the molecular biology underlying NNI tolerance in honeybees.
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Introduction
There are a number of factors implicated in the decline of honeybee health.  One of the main
contributors is the use of neonicotinoid insecticides (NNIs) on agricultural crops.  While these pesticides
have been banned in Europe, they are still widely used in North America (Gross, 2013). Neonicotinoids
are a class of agricultural pesticides that are chemically similar to nicotine and can be subdivided into
three classes: nitromethylenes, N-nitroguanidine and N-cyanoamidine neonicotinoids (Goulson et al.,
2013).  Their widespread usage as insecticides arises from their highly agonistic properties to insect
nicotinic acetylcholine receptors (nAChRs), compared to the mammalian nAChRs (Tomizawa et al.,
2005). In honeybees, acute levels of neonicotinoids can cause a variety of issues such as: impairing their
immunity so that they are more susceptible to pathogens (Di Prisco et al., 2013); decreasing queen
reproductive health (Williams et al., 2015); as well as causing learning and memory dysfunction in
worker bees which can impact foraging (Henry et al., 2012).  Chronic levels of neonicotinoids cause bee
paralysis and eventually death (Blaquiere et al., 2012).  Honeybees also tend to be more sensitive to
N-nitro neonicotinoids (imidacloprid, clothianidin, thiamethoxam) compared to the N-cyano class (Iwasa
et al., 2004).
Several researchers have shown that groups of bees within the same colony, or bees from different
colonies or races, exhibit different health outcomes when exposed to NNIs.  Laurino et al., found that
there was a larger variation of honeybee acute oral toxicity of imidacloprid in the Apis mellifera mellifera
colony compared to other honeybee genotypes Apis mellifera ligustica, and Apis mellifera carnica (2013).
Suchail et al. (2000), also found similar results when comparing the LD50s of imidacloprid of Apis
mellifera mellifera and Apis mellifera caucasica. Apis mellifera mellifera had a higher contact tolerance
to imidacloprid (with an LD50 of 24 ng/bee compared to 14 ng/bee after contact application), however
they both displayed similar oral toxicity results. A meta analysis was done in 2011 that also showed a
wide variation in acute honeybee toxicity based on 13 studies (Cresswell, 2011).  However, this large
variation may be due to different methodologies, and environmental conditions rather than actual
inherited resistance. Neonicotinoid resistance or tolerance has been previously documented in other insect
species, and is mostly caused by an increase in expression in one or more of the cytochrome P450s that
metabolize NNIs, or mutations in the nAChR which would reduce neonicotinoid binding (reviewed in
Table 1.) (Bass et al., 2015).
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Our group (Tsvektov and Zayed, in prep) carried out an experiment to understand the genetic and
molecular biology underlying NNI sensitivity in honey bees. Briefly, Bees within the same colony were
exposed to 29 ppb of clothianidin (the average LD50 obtained from the U.S. Environmental Protection
Agency Pesticide Ecotoxicity database) and had shown a large variation of mortality based on their
patriline (or dad’s genetics), implying a certain level of inherited resistance to clothianidin.  Specifically,
they calculated a broad sense heritability value of 37.8% (Tsvetkov and Zayed, in prep).  Honeybees are
haplodiploid organisms, meaning in a typical honey bee colony, all worker bees are female and share the
same mother, the queen bee.  Because the queen is polyandrous (i.e. mate with many males), all worker
bees sharing the same father are 75% related to one another, while workers with different fathers are 25%
related.  On a colony level any source of genetic variation could then only come from the males that the
queen mates with.  Paternal lineage can lead to phenotypic diversity within colonies, as demonstrated for
sucrose responsiveness (Scheiner & Arnold, 2010), and hygienic behaviour (Perez-Sato et al., 2009). In
Tsvetkov and Zayed’s study, paternal lineage has been linked to the survivability of bees fed the LD50
dose of clothianidin.
The goal of my MSc is to explore the mechanisms responsible for the inherited differences in
neonicotinoid resistance in honey bees.  To achieve this, RNAseq was used to compare gene expression in
the ventriculus, Malpighian tubules, and brains of honey bees from patrilines exhibiting high resistance
and comparing them to patrilines with low resistance to NNIs.  We used these datasets to test the
hypothesis that inherited NNI resistance may be caused by an upregulation in detoxification enzymes in
key tissues associated with detoxification.  I also carried out an analysis to explore tissue-specific
detoxification patterns of bees exposed to a sublethal dose of clothianidin.
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Chapter 1
Transcriptomics of neonicotinoid tolerance in the honey bee
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1.1 Introduction
Neonicotinoids (NNIs) are now the most widely used insecticides in the world and were developed
in response to pest resistance to other chemical pesticides in agricultural crops (Jeschke et al., 2011).
NNIs are systemic pesticides, where a coating is applied on the seed of a plant.  The NNI is then absorbed
by all parts of the plant as it continues to grow allowing it to be resistant to multiple pests at once,
(Bromilow & Chamberlin, 1995).  Honey bees are exposed to NNIs through multiple routes, such as
pollen and nectar of agricultural crops, however presence of NNIs in wild plants near NNI treated crops
has also been detected (Tsvetkov et al., 2017, Botlas et al., 2016).  The literature on the effects of NNIs on
honeybees has been very mixed.  There are a multitude of studies linking NNI exposure of bees to altered
learning and memory in foragers (Decourtye et al. 2004, Han et al. 2010, El Hassini et al. 2008).  NNI
exposure, even at sublethal doses have been linked to reduced immunity (Di Prisco et al., 2013) as well as
increased mortality (Vidau et al., 2011). However there have also been studies that have contradicted
these findings (Williamson et al., 2013) and found no negative effects of NNI exposure on
honeybees.
One possibility that may explain the variation in how NNIs influence bees is that some bee
genotypes may be partly resistant to NNIs. Many insects have become resistant to neonicotinoids, either
by an upregulation of their CYP enzymes, mutations in their CYP enzymes causing them to metabolize
NNIs more effectively, or through mutations of their nAChRs (NNIs are no longer able to bind) (Table 1).
There has been some indirect evidence of genetic predispositions that impact NNI survivability in
honeybees.  Woodcock et al. (2017) found that there were negative effects associated with honeybees near
neonicotinoid treated crops in Hungary and the United Kingdom.  In the same study, colonies in Germany
had no effect associated with being near NNI treated crops, and experienced a higher number of egg cells.
Laurino et al. (2013) also noted differences in LD50 doses between different Apis mellifera subspecies
and colonies.
NNIs are first metabolized in the honeybee by cytochrome p450s.  There are three P450 enzymes
unique to the Apis family responsible for metabolizing neonicotinoids, CYP9Q1, CYP9Q2, and CYP9Q3.
They’re a family of cytochrome p450 mono oxidative genes which have a high affinity for the N-cyano
NNIs, and have limited activity against nitro- substituted NNIs, with CYP9Q3 metabolizing the
compounds the most efficiently (Manjon et al., 2018). The CYP9Q subfamily are highly expressed in the
Malphghian tubules, ventriculus and the brain of the honeybee, which is consistent with the fact that these
tissues are where xenobiotic detoxification would typically take place (Manjon et al., 2018, Vannette et
al., 2015).
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Tsvetkov & Zayed (in prep.) were able to link NNI resistance with patriline genetics in two
separate honey bee colonies.  Bees were given the LD50 dose, and after 24 hours, they were examined to
see if they were dead or alive. Bees were then genetically fingerprinted to determine their patriline (dad),
and patriline survival was then compared within each family (Figure 1A).  There was a strong link
between patriline and survival, thus leading them to the conclusion that NNI resistance is heritable in
honeybees.  They estimated broad sense heritability for LD50 survival at 37.8%.  The CYP9Q1,
CYP9Q2, and CYP9Q3 genes of the patrilines were also sequenced, and there was evidence of mutations
present in the CYP9Q3 gene which was statistically associated with NNI resistance; bees with a specific
group of haplotypes having 88% chance of surviving the LD50 dose of clothianidin.  Tsvetkov & Zayed
found that, for non-resistant bees (or bees which did not have the CYP9Q3 haplotype that corresponded to
a higher survival), the CYP9Q1 haplotype still had an impact on survival.  Non-resistant patrilines with a
CYP9Q1 specific set of haplotypes have an average survival of 35%, while non-resistant patrilines with a
different CYP9Q1 haplotype could have an average survival of 64%.  Since we know which enzymes are
responsible for NNI metabolism, and that a genetic predisposition exists which can alter NNI resistance,
we can begin to explore tissue specific effects of NNIs, and the potential downstream effects caused by
lower resistance to sublethal doses of NNIs.  Sublethal doses of NNIs have been shown to cause
morphological changes in the midgut and the Malpighian tubules (Catae et al., 2014, De Almeida Rossi et
al., 2013, Oliveira et al., 2013).  It has also been proven that field realistic doses can have an impact on
the honeybee brain on a physiological level (reviewed by Cabirol and Haase, 2019) which can translate
into altered honey bee behaviour.  Our transcriptomic analysis will allow us to explore these effects
between resistant and non-resistant bees by comparing differentially expressed genes between the two
groups.  It could give us insight into some of the molecular mechanisms involved in neonicotinoid
toxicity, and will allow us to explore the effects that could potentially be causing the cellular changes
associated with NNI resistance.
In this chapter, we aim to understand the molecular basis of NNI resistance by comparing global
gene expression of resistant and non-resistant bees that have been exposed to a field realistic dose of
clothianidin (Figure 1B).  Additionally, we compared the transcriptomes of bees with different CYP9Q
haplotypes.  These analyses were conducted for 3 tissues previously known to be important for NNI
detoxification: the Malpighian tubules, the brain and the ventriculus (Figure 2).  By exploring different
tissues, we can explore where the majority of the transcriptomics occur, and it allows us to explore other
off-target impacts neonicotinoids may have, particularly on bees that are unable to metabolize them.
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1.2 Materials and Methods
Experimental overview: Clothianidin exposure and bee collections
Bees were exposed to clothianidin in experiments carried out by Nadia Tsvetkov, a PhD student in
the Zayed lab (Tsvetkov and Zayed, in prep).  In summary, 9-day-old bees from two colonies were starved
for 4 hours, and then fed 20 ul of sugar solution which either contained a field realistic dose (4.6 ppb),
LD50 dose (29 ppb) or no (control) clothianidin for 2 hours.   Only bees which had consumed 90% of
their solutions were used in the analysis.  The bees were then given a regular sugar solution (50% w/v)
and after 24 hours, they were either scored as dead or alive before being frozen at -80oC.  They were then
classified based on their patriline using microsatellite genotyping of 11 loci, following established
methods (Tsvetkov & Zayed, in prep).   Patrilines with the highest proportion of bees that survived the
LD50 dose after 24 hours were classified as “Resistant”. Similarly, patrilines with the highest proportion
of bees that did not survive the LD50 dose after 24 hours were classified as “Non-Resistant”.  For the
field realistic exposure, bees were exposed for 2 hours, and bees which had consumed over 90% of their
sugar solutions were used in the analysis. After 24 hours these bees (they all had 100% survival due to the
dose being sublethal) were then taken and frozen at -80oC.  A sublethal dose was chosen for
transcriptomic analysis because it would be more representative of typical field exposure (Tsvetkov et al.,
2017).  As summarized in Figure 1B, we compared the transcriptomes from patrilines exhibiting the
highest resistance from the LD50 studies to the patrilines exhibiting the lowest resistance with 3 patrilines
within each group.  Within each patriline we pooled the brain, Malpighian tubules, and ventriculus of 5
bees separately for each organ.
Dissections and RNA extractions
Frozen bees were placed in 1 ml of chilled RNAlater and thawed over ice.  We performed
dissections of the brain, Malphighian tubules, and ventriculus and kept them at -80oC until RNA could be
extracted.  RNA extractions were completed using the Qiagen miRNeasy Mini kit.  Briefly, we added
700ul of Qiazol lysis reagent to the tissues and homogenized the solution using a pipette.  The protocol
provided by the manufacturer was then followed in order to extract the RNA. We added 140 ul of
chloroform to the mixture and shook the tubes before allowing them to sit at room temperature for 5
minutes.  We then spun the mixture at 12 000 g for 15 minutes, and 1.5 volumes of 100% ethanol was
added to the upper phase.  Once a precipitate had formed, we ran the mixture through aRNeasy spin
column.  700 ul of buffer RWT was then added, and once again run through the column.  We added 500 ul
of buffer RPE through the column twice before drying the membrane.  30ul of RNA-free water was then
run through the column (this water now contains the RNA). RNA quality and quantity was assessed using
a NanoDrop ND-1000 UV-Vis.
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Pooling and Sequencing
Based on recommendations for illumina sequencing, we aimed for a minimum RNA
concentration of 100ng/ul (or a total of 1500 ng of RNA). The ventriculus, brains and Malpighian tubules
of 5 individual bees from each patriline were pooled separately based on their organ (i.e. all the brains of
a patriline were pooled together). We had a total of 3 resistant patrilines, and 3 non-resistant patrilines and
18 pools in total.  To ensure equal representation for each bee, we added 300 ng of RNA to each pool
(1500ng/5bees).  Samples were then kept at -80oC until being shipped for sequencing at Genome Quebec.
Libraries preparation and 100 bp pair-end sequencing using the Illumina NovaSeq 6000 S4, were carried
out by Genome Quebec’s sequencing facility (Montreal, QC). On average, we sequenced 233 million
reads from each sample.
Assembly, annotation and transcriptomic analysis
Once the reads were received from Genome Quebec, they were trimmed using Trimmomatic,
filtering out reads less than 50 base pairs (Bolger et al., 2014).  Reads were aligned and indexed against
the Apis mellifera genome (Amel_4.5) using STAR (Dober et al., 3013).  MultiQC (Ewells et al., 2016)
was run on all files to ensure quality alignments. Htcounts were used to count the aligned reads (Anders et
al., 2014).  Differential Expression analysis was carried out using EdgeR (Robinson et al., 2010). We
used a Benjamini adjustment (Benjamini & Hochberg, 1995) of raw p-values, and genes with a False
Discovery rate (FDR) of  < 0.05 were considered to be differentially expressed.  We first compared gene
expression profiles of resistant vs non resistant patrilines (Figure 1). The bees were then compared based
on their haplotypes.  Because one of the haplotypes only had one biological replicate, we analyzed it
using NOIseq (Tarazona et al., 2015).  NOIseq simulates replicates under the assumption that the read
counts follow a multinomial distribution.  This allows the algorithm to make up for lack of replicates
allowing us to view biological trends.  Following the NOIseq recommendations (Tarazona et al., 2015),
we normalized the data using the trimmed means methods and filtered out low counts (cpm <1).  NOIseq
does not output a p value, but rather an estimated probability value, they recommended a probability
value of 0.9 for simulated data, however we chose a more stringent estimated probability of 0.95 to
identify differentially expressed genes for this analysis. Since NOIseq simulates data, we view these
results as biological trends rather than significantly expressed genes.
GO analysis
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We used ShinyGO for enriched functional analysis (Ge et al., 2020) of Gene Ontology (GO)
Processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) categories, using a false discovery
rate cut off of 0.05.  We also performed a brief literature search on genes that hadn’t been grouped into
any of the enriched GO functions.
1.3 Results
The survival rates from the LD50 trials of the patrilines are shown in Table 2, as well as their
haplotypes (data provided by Nadia Tsvetkov).  Non-resistant patrilines had an average survival of 40%
while resistant patrilines had an average survival of 96% (Table 2, data provided by Nadia Tsvetkov).
Transcriptomes were sequenced at an average read length of 100 bp and an average of 133 million reads
per sample. Filtered reads had  >99.9% alignment to the bee reference transcriptome (Figure 3).
Resistant (R) vs. Non-Resistant (NR)
We found no differentially regulated genes in the Brain between resistant and non-resistant
honeybees.  We did find 1 gene, XR_003306097.1, an uncharacterized protein (logFC =-3.35, p<0.0001,
FDR < 0.0001), that was upregulated in the ventriculus in the NR honeybees..  Clustering by resistance
was only seen in the Malpighian tubules (Figure 4). Resistant patrilines had 1 significantly upregulated
gene in the Malpighian tubules: fatty acid amide hydrolase 2-B (logFC =1.12, p<0.0001, FDR < 0.0005).
In the Malpighian tubules of NR patrilines, 95 genes were upregulated (Supplementary Table 1).  Of the
95 upregulated genes there were 37 uncharacterized genes.  Interestingly, caspase-3, one of the main
regulatory genes involved in apoptosis, was upregulated in non-resistant bees (logFC =-1.19, p<0.0005,
FDR < 0.05).  Another gene, involved in osmotic regulation in the Malpighian tubules such as the sodium
potassium calcium exchanger 3 was also upregulated (logFC =-1.50, p<0.0005, FDR < 0.0005). Three
SOX transcription factors were also seen to be upregulated in the NR group such as Sox-2(logFC =-2.56,
p<0.0001, FDR < 0.0001), and Sox- 13 (logFC =-3.56, p<0.0001, FDR < 0.001) and Sox 21-B (logFC
=-1.71, p<0.0005, FDR < 0.05).  CYP6A-4 was the only cytochrome P450 to be found to be upregulated
in the NR group (logFC =-1.47, p<0.0005, FDR < 0.05). Dyenin-beta ciliary (involved in ciliary
movement) (logFC =-4.30, p<0.0001, FDR < 0.005) , and uncharacterized LOC107964495 (logFC
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=-4.24, p<0.0001, FDR < 0.001) were the most upregulated genes in our gene set (Supplementary Table
1).
Gene ontology analysis of the up-regulated genes in the Malpighian tubules of non-resistant bees
indicated proteolysis (GO:0006508) as the only enriched biological process (BP) (p < 0.016).  This group
includes endothelin-converting enzyme homolog, trypsin, disintegrin and metalloproteinase
domain-containing protein 10-like, putative serine protease K12H4.7, caspase-3, aminopeptidase N (Gene
ID: 551180), aminopeptidase N (Gene ID: 551224), and serine protease 53. Up-regulated genes in the
Malpighian tubules of non-resistant bees were also enriched for multiple molecular functions (Figure 5),
including:  peptidase activity (GO:0008233), peptidase activity-acting on L-amino acid peptides,
beta-N-acetylhexosaminidase activity (GO:0004563), hydrolase activity (GO:0016787), hexosaminidase
activity (GO:0015929), endopeptidase activity (GO:0004175), metallopeptidase activity (GO:0008237),
catalytic activity, acting on a protein (GO:0140096), aminopeptidase activity(GO:0004177), catalytic
activity (GO:0003824), serine-type peptidase activity (GO:0008236), and serine hydrolase activity
(GO:0017171).
Expression differences between CYP9Q haplotypes
An analysis of differences in SNPs among CYP9Q1-3 genes revealed differences in survival
between different CYP9Q haplotypes (Tsvetkov unpublished). The first indicator of survival was the
SNPs present in the CYP9Q3 enzyme.  Our resistant group (P7, P24, and P11) all had CYP9Q3
haplotypes that led to a survival rate in the LD50 study of 96% (Table 2).  Our NR group (P21, P1, P8) all
had CYP9Q3 haplotypes from the non-resistant group which lowered their survival.  Within the NR
group, P1 and P8 had SNPs in their CYP9Q1 gene leading to differences in survival as well.  P1 and P8
had a survival average of 34.5% in the LD50 study (hereafter called the low survival haplotype), while
P21 had a CYP9Q1 haplotype the led to a survival rate of 53% (hereafter called the intermediate survival
haplotype).  The purpose of this analysis was to compare the three haplotypes (noted R for high survival,
P1P8 for low survival, and P21 for intermediate survival) individually in order to examine the molecular
changes that occur as a result of their SNPs.  Making transcriptomic comparisons between each NR
haplotype  (low vs intermediate) will allow us to study the biological response associated with having a
lower tolerance  compared to the haplotype that exhibits an intermediate tolerance. In this section, we
compare low, intermediate and high survival groups to explore the range of responses associated with
NNI exposure.
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Low survival vs intermediate survival
When comparing the low survival group (34.5% survival) and the intermediate survival group (53%
survival), we found the largest differences of gene expression in the Brain (Supplementary Table 3). 37
genes were upregulated in the intermediat group, including 3 P450s:  CYP9Q2 (FC =1.10 , p<0.05),
CYP6A17 (FC =1.75 , p<0.05) and cytochrome b5 (FC =1.84 , p<0.05).  Other interesting differentially
expressed genes include death associated protein 1, which is involved in apoptosis (logFC =1.41 , p<0.05)
.  The top 30 enriched biological processes included categories (p<0.005) such as transmembrane
transport (GO:0090662) and establishment of localization (GO:0051234) (Supplementary Table 7).  The
intermediate survival group had upregulated genes enriched in 6 cellular component (CC) categories,
most of them having to do with the membrane (p<0.05). Genes upregulated in this group were enriched
for the following molecular functions:  In catalytic activity (GO:0003824) (p<0.005), binding (p<0.05), 6
genes were also involved in oxidoreductase activity (GO:0016491) (p<0.05).  Upregulated genes in the
intermediate survival group were enriched for 6 KEGG pathways: MTOR signaling (p<0.0005),
phagosome (p<0.0005), oxidative phosphorylation (p<0.001), metabolic pathways (p<0.0005),
phagosome (p<0.0005) and carbon metabolism (p < 0.005).
In the Brain, 210 genes were found to be upregulated in the low survival group compared to the
intermediate survival group including: the nACHRα-1 subunit  (FC =-1.59 , p<0.05), AChE-2 (FC =-1.68,
p<0.05) and choline-O- acetyl transferase (responsible for the synthesis of acetylcholine) (FC =-1.12 ,
p<0.05).   Acetyl-coenzyme A synthetase (FC =-1.15 , p<0.05), muscarinic acetylcholine receptor DM1
(FC =1.72 , p<0.05), vesicular acetylcholine transporter (FC =-1.50 , p<0.05) were also upregulated in
the low survival group.  Other upregulated genes involved in neural signaling include: the octopamine
receptor  (FC =-1.23, p<0.05), the alpha-2A adrenergic receptor (FC =-1.45, p<0.05), vesicle associated
membrane protein 2 (FC =-1.06, p<0.05), and neuroendocrine convertase 2 (FC =-1.45, p<0.05)
(Supplementary Table 3). Our gene list had enrichment in 21 BP categories, the top ones being
establishment of localization (GO:0051234) (p<0.01), transport (p<0.01), and localization (p<0.01) with
24 upregulated genes in each category.  21 cell component terms were enriched with 52 upregulated genes
being involved with the membrane (p<0.005).  Of the molecular function categories, binding was
enriched with 77 genes being upregulated (p<005) as well as hydrolase activity (GO:0016787) (p<0.05).
2 KEGG pathways were enriched, the phagosome, and the longevity regulation pathway (p<0.05)
(Supplementary Table 8).
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In the Malpighian tubules, we saw less differences between the low survival and intermediate
survival with only 11 genes upregulated in the intermediate survival group.  The low survival group had
18 upregulated genes including upregulation of the CYP9Q3 protein (FC=1.35, p<0.05).  We found no
GO enrichment from the upregulated genes of the P21 haplotype.  The only biological processes category
that was enriched was proteolysis (GO:0006508) (p<0.05), with 4 genes in our list being involved.  There
was no significant enrichment in the cellular component GO category.  17 molecular function categories
were enriched (Supplementary Table 9) with 9 genes being involved in catalytic activity(GO:0003824)
(p<0.05) and 7 having hydrolase activity (GO:0016787) (p<005).
Only one gene, Mjrp1 (FC=7.54, p<0.05), was upregulated in the ventriculus of bees in the
intermediate survival group. The low survival group had two upregulated genes in the ventriculus:
vitellogenin (FC= 3.88, p<0.05) and LOC107963975 (FC =2.41 p<0.05).
Intermediate survival vs high survival
When comparing intermediate vs high survival, we found 2 upregulated genes in the high survival
group: alpha-amylase (FC = 2.18, p<0.05) and NPC intracellular cholesterol transporter 2 homolog a  (FC
= 1.75, p<0.05).  No upregulated genes were found in the intermediate group. In the ventriculus there
were 2 genes upregulated in the high survival group: transcription factor SPT20 homolog, and
take-out-like carrier protein.  The intermediate survival group had 5 upregulated genes compared to the
resistant group including CYP9Q3 and CYP336A1.  Lastly, in the Malpighian tubules there were 19
genes upregulated in the intermediate group compared to the high survival group.  These genes were not
enriched for any gene ontology terms.  The high survival group also had 5 upregulated genes in the
Malpighian tubules: melitten (FC=4.58, p<0.05), hexamerin 70a (FC= 1.70, p<0.05), CYP9Q3 (FC =
2.11, p<0.05), facilitated trehalose transporter Tret1 (FC = 2.33, p<0.05), and transcription factor SPT20
homolog (FC = 2.17, p<0.05).
Low survival vs high survival
There were no differentially expressed genes in the brain between the low survival group and the
high survival group. In the Ventriculus, we found one upregulated gene in the low survival group (
uncharacterized LOC724439, FC = 2.29, p<0.05), and two genes upregulated in the high survival group
(take-out-like carrier protein, FC =1.63, p<0.05, and trypsin-7 FC=1.32, p<0.05) (Supplementary Table
6).  There were 22 upregulated genes in the Malpighian tubules of the low survival group and 3 genes
upregulated in the high survival group: melittin (FC= 3.87, p<0.05), transcription factor SPT20 homolog
(FC= 2.25 p<0.05), NPC intracellular cholesterol transporter 2 homolog a (FC= 1.87, p<0.05)
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(Supplementary Table 6). In total there were 8 biological processes enriched in upregulated genes in the
Malpighian tubules of the P1P8 group.  Of these upregulated genes, 11 of the 22 were involved in
metabolic processes(p<0.002) and 7 were involved with proteolysis (GO:0006508) (p<0.00001) in the
biological processes categories. In the 15 enriched molecular function categories, 11 genes were involved
in hydrolase activity(GO:0016787) (p<0.00001), and 12 were involved in catalytic activity (GO:0003824)
(p<0.0001) (Supplementary Table 10).  11 of the upregulated genes also overlapped with the genes that
were upregulated in the intermediate survival group when compared to the low survival group.
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1.4 Discussion
The goal of this experiment was to understand the molecular basis of neonicotinoid resistance,
with our initial hypothesis being that we would see an upregulation in detoxification enzymes in our
resistant patrilines.  Our data shows that this is not the case, seeing as there were no upregulated
detoxification genes found in our resistant patrilines when exposed to a sublethal dose of clothianidin.
This suggests that it is allelic differences between patrilines that account for the majority of the resistance
seen between our patrilines. The mutations in the CYP9Q enzymes can either allow more efficient
metabolism of NNIs leading to resistance, or have the opposite effect and lower the metabolism of NNIs.
That being said, analysis of the upregulated genes in the non-resistant group can still give us insight into
the molecular mechanisms associated with NNI toxicity.
GO analysis revealed that there was an upregulation of proteolysis and catabolic processes in the
Malpighian tubules of honeybees that are not resistant to neonicotinoids. Africanized honeybees that have
been exposed to sublethal doses of thiamethoxam had altered Malpighian tubule cells, specifically in the
basal labyrinth (Catae et al., 2014).  The basal labyrinth is a specialized cellular structure in the
Malpighian tubule cells that helps maximize contact with the hemolymph to increase the uptake of
metabolized substances (Cruz-Landim,1998).  The exposed bees had visible disorganization in this
region, while the microvilli and mitochondria remained intact (Catae et al., 2014). After 3 days of
exposure, there was a visible increase in smooth endoplasmic reticulum as a way to increase cellular
detoxification. Finally, after 8 days of sublethal exposure, there were major alterations in the Malpighian
tubules with the loss of basal labyrinth, the loss of mitochondria, and dilated microvilli (Catae et al.,
2014).   A similar effect was seen in De Almeida Rossi et al.’s study where they found a reduction in the
basal labyrinth, after 3 days of sublethal exposure of the LD50/10 of imidacloprid in africanized
honeybees (2013).  The authors also found an increase of pyknotic nuclei, the irreversible condensation of
the chromatin in the nucleus, and an increase in cytoplasmic vacuolization (De Almeida Rossi et al.,
2013).  Our RNAseq data seems to be consistent with these studies where the upregulation in genes
involved in catalysis, and proteolysis in NR patrilines may be contributing to this reorganization of the
Malpighian tubule cells in order to increase detoxification of clothianidin, which may have either
non-functioning, or less effective, CYP9 enzymes because of mutations found in these patrilines.
Malpighian tubule cells have been known to self renew through multipotent stem cells (Singh et
al., 2007).  The upregulation of Sox transcription factors (known to regulate cell differentiation and
development) in our NR group suggests a shift in cell differentiation in these cells as a result of
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clothianidin exposure.  This could have long term implications and may explain the major alterations in
the Malpighian tubules seen in previous studies. There also was an upregulation in multiple genes
involved in ciliary movement, LOC726309 protein artichoke, dynein beta chain, ciliary,
hydrocephalus-inducing protein-like were all upregulated in NR bees.  While there isn’t cilia present in
the honeybee Malpighian tubules, they do have the presence of microvilli (Noecelli et al., 2016). The
upregulation of these genets suggests that there can be an  increase in microvilli  movement which may
lead to an increased secretory activity of the Malpighian tubules.  The sodium calcium potassium
exchanger is involved with osmotic regulation and transepithelial secretion in the Malpighian tubules, and
helps regulate the water secretion in the Malpighian tubule cells (Noecelli et al., 2016).  We had found
that this was upregulated in the Malpighian tubules of our bees.  There could be a disruption in the ionic
and fluid homeostasis in these cells and cells may be attempting to compensate for the lack of
detoxification by increasing the propulsion of fluids from the hemolymph and body, into their waste. Due
to their limited capacity to break down clothianidin, likely caused by mutations in CYP9Q enzymes, the
non-resistant group appear to be experiencing altered Malpighian tubule detoxification.  They may be
trying to reorganize their cellular structures in order to increase detoxification capacity, or may be
overwhelmed with the dose of clothianidin leading to cell death. We can also see this with the
upregulation of caspase-3, a protein involved in apoptosis as well as the increase in proteolysis.
There have been many studies that have examined shifts in the brain as a response to NNIs
(Table 3).  In particular, Oliveira et al., 2013 looked at the side effects of the brain and midgut
(ventriculus) of bees that were exposed to 1/10 and 1/100 of the LD50 of thiamethoxam for 3 days.
Through histochemical analysis they found that the mushroom bodies and kenyon cells had significant
morphological alterations indicative of cell death. Christen et al., looked at the transcriptomic profile of
the brains of bees in response to 3 and 30 ppb of clothianidin (our bees had 4.6ppb).  Bees were fed the
solution ad libitum for 48 hours before being analyzed. They found 18 genes to be differentially
expressed, compared to the control, 4 were upregulated while 14 were downregulated (Christen et al.,
2014).  There were no differences in gene expression in the brain however our bees had different exposure
conditions which may have not been enough to cause a gene expression shift in the brain.  Alternatively,
because we had no unexposed group, gene expression shifts in the brain may be happening with all the
bees, but is undetectable without an unexposed control.
With regard to the ventriculus, it has been reported that there has been a change in morphology to
the midgut, such as cytoplasmic vacuolization, increased apocrine secretion and increased cell
elimination., 1 day after being exposed to sublethal doses of thiamethoxam orally (Olivereira et al., 2013).
14
In Catae’s et al.’s study they had also noticed a drastic increase in apoptosis in the cells in ventriculus of
honeybees exposed to sublethal doses compared to the control group (2014).  We did not see any
difference between the R and NR groups.  The ventriculus effect may be happening to all bees studied,
regardless of resistance which is why we didn’t see any changes and had we included a un-exposed
control group, this phenomenon may have been detected in our data.  We may also have not seen this
effect due to the different exposure conditions between the studies.
Haplotype
Tsevetkov & Zayed (in prep.) found that CYP9Q sequence had an effect on honeybee survival to
the LD50 dose of clothianidin.  CYP9Q3 haplotype determined whether or not a bee could be considered
resistant (88% survival to an LD50 dose of clothianidin) or non-resistant.  Within the non-resistant group,
CYP9Q1 played a role on whether a patriline had a low survival (34% survival to an LD50 dose of
clothianidin), or an intermediate survival (53% survival to an LD50 dose of clothianidin).  By comparing
the differentially expressed genes between the NR haplotypes, it can give us information regarding the
downstream effects of the CYP9Q1 mutations with regards to NNI toxicity.
We observed the largest changes in expression between the NR haplotypes (P1P8 vs P21, low vs
intermediate survival) in the brain.  The intermediate survival group was found to have an upregulation of
mono-oxygenase activity with CYP9Q2 being upregulated. The data implies that in order to compensate
for a less effective CYP9Q3 protein, this group may be upregulating CYP9Q2 and other P450s proteins to
help breakdown clothianidin, even at sublethal doses. This difference between the CYP9Q1 haplotype
may contribute to the higher survival rate between the intermediate and low groups.  Our results aren’t
conclusive however, since we only had one patriline to explore this effect.
Another notable difference between the two NR haplotypes was that the intermediate survival
group had an upregulation in genes involved with mTOR signaling.  mTOR signaling has been proven to
have involvement with learning and memory (Graber et al., 2013).  The 3 upregulated genes involved
with mTOR signalling were V-ATPases which are all involved with activating mTORC1.  This suggests
that bees in the low survival group might have altered learning and memory due to the fact that they have
15
lower expression of mTOR signalling genes which  might help explain some of the learning
dysfunctionalities seen in honeybees exposed to sublethal doses of neonicotinoids (Henry et al., 2012).
We found that the low survival compared to the intermediate survival had an upregulation of 210
genes in the brain.  Based on our resistance analysis (R vs NR), there doesn’t seem to be a major effect in
the brain as a response to NNIs in a short period of time between resistant and non-resistant groups. Even
when the low and intermediate survival groups were compared to the resistant group individually, there
wasn’t a large number of DEGs.  Thus, the large differences may be a result of haplotypes within NR
patrilines and could potentially play a role as to why the intermediate group has a higher survival rate
when exposed to the LD50.  We found that ACHe-2, the nAChRα subunit, and other neuroreceptors were
upregulated in the low survival group.  Christen et al., did notice a significant increase in the nAChRα
subunit in the honeybee brain 72 hours after being orally exposed to 3 ppb of clothianidin, while there
was a slight increase (n.s.) after 24 hours (2016). Seeing as clothianidin is an agonist to the nAChRα
receptors  a slight upregulation in the low survival as a response to small amounts of NNIs that could
potentially play a larger role when it comes to more constant sublethal exposures, or at higher dosages.
The upregulation of these receptors may indicate that the low survival group is having a harder time
metabolizing the NNIs, and are thus upregulating these receptors in order to compensate. Additionally the




Our study shows that even sublethal doses can have an impact on honeybees that are not resistant
to neonicotinoids.  When comparing resistant and non-resistant patrilines, we found non-resistant
patrilines had an upregulation in genes involved in proteolytic processes that may be involved in the
structural damage of Malpighian tubules seen in previous studies.  Our study gives insight into the
toxicodynamics of honeybees that have different levels of resistance to neonicotinoids, and the
mechanisms of how their susceptibility greatly increases depending on their genetics.  We also found
transcriptomic changes between non-resistant bees that had different CYP9Q1-3 haplotypes (which had
previously resulted in different levels of survival (Tsvetkov & Zayed, in prep.). Once again, examining
these molecular changes gives us insight into the mechanisms that result in long term NNI toxicity. This
helps us understand the conflicting results in the literature regarding honeybee learning as a result of NNI
exposure.  Future studies should include what sort of impact these changes may have on a colony level, as
well as long term expression studies based on resistance/haplotype.
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Chapter 2




Most of the RNA-seq tissue specific data in response to NNIs has either been in the brain, or whole
bee expression (Table 3). NNIs target the nACHr, however as shown by (Catae et al., 2014), there was a
rise in apoptosis in the ventriculus after 24 hours as a response to sublethal doses of thiamethoxam, and
the Malpighian tubules had suffered a major loss in their basal labyrinth.  Comparing gene expression in
different tissues of bees exposed to NNIs can help us understand which tissues are primarily involved in
detoxifying NNIs as well as understand the downstream effects of NNI exposure on honey bees.
NNIs are detoxified in the honeybee through 3 major enzyme families: cytochrome P450s (P450s),
glutathione transferases (GSTs) and carboxylesterases (CaEs) (Li et al., 2007).  The P450s are involved
with phase 1 metabolism, where they catalyze oxidation and demethylation reactions (Magesh et al.,
2017).  GSTs catalyze the metabolism of NNIs in phase 2 by conjugating the thiol group from glutathione,
to the electrophilic center of toxic compounds or other reactive oxygen species.  As a result, the
compound is now more water soluble and targets the molecule to specific glutathione multidrug exporters
(GSH) (Esther et al., 2015).  Lastly, carboxylesterases are responsible for the hydrolysis of carboxyl esters
into the corresponding alcohol and carboxyl acid, and have been shown to be involved with the formation
of NNI metabolites.  Suchail et al., has reported distribution of imidacloprid and its metabolites
throughout the whole body of the honeybee suggesting metabolism occurs in multiple tissues, outside the
midgut (the first line of defense when NNIs are orally ingested) (2004). Most of the studies looking at
NNI detoxification pathways have used in-vitro metabolism assays, or toxicity bioassays with the
presence/absence of certain enzyme inhibitors/inducers (reviewed by Magesh et al., 2017).
The goal of this chapter is to explore global gene expression in three tissues of honey bee workers
exposed to a sublethal dose of clothianidin: the brain, Malpighian tubules and ventriculus.  We chose
these tissues based on previous research. For example, many studies have linked NNI exposure to altered
honeybee behaviour and learning (El Hassani et al., 2008), suggesting that NNIs impact the honey bee
brain transcriptome. We also examined the ventriculus (or midgut) as it constitutes the first lines of
defense when NNIs are ingested orally (Kakamand et al., 2008).  Finally, we also studied the Malpighian
tubules because they play an important role in detoxification (Beyenbach et al., 2010). Moreover, one
previous study (Manjon et al., 2018) clearly established that all three tissues play an important role in
specifically detoxifying NNIs. We specifically characterized the expression patterns of three major
detoxification enzyme families (GSTs, CaEs, and P450s) and compared them between the three above
mentioned tissues.
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2.2 Materials and methods
Dissections, RNA extractions and RNA sequences were performed as described in section 1.2, above.
We took the RNAseq expression data of all bees (resistant and non-resistant) for each organ and compared
the organs against one  another.
Data analysis
We performed an ANOVA to compare tissue specific expressions of the midgut, brain and
Malpighian tubules using the EdgeR program (Anders et al., 2014).  We explored the functional role of
differentially expressed genes by carrying out a gene ontology analysis using the ShinyGO software on
uniquely upregulated genes (Ge et al., 2020).  A gene was considered uniquely upregulated if it was
upregulated relative to each other tissue.  We then examined the top 30 enriched GO categories for each
organ.  Venn diagrams were created with the DEGs using an online software
(http://bioinformatics.psb.ugent.be/cgi-bin/liste/Venn/calculate_venn.htpl). We specifically focused on
the following subsets of Apis mellifera genes involved in detoxification:  cytochrome p450s,




We found 6,792 differentially expressed genes between the 3 Tissues.  855 transcripts were
uniquely upregulated in the Ventriculus, 2406 were uniquely upregulated in the Malpighian tubules, and
3527 transcripts were uniquely upregulated in the Brain (Figure 5).
Gene ontology analysis:
We compared the GO categories enriched for uniquely upregulated genes of each organ
(Supplementary Table 11).  Enrichment analysis revealed that the uniquely upregulated genes in the
ventriculus had overrepresentation in 20 biological processes with 204 genes being involved in metabolic
processes, and 196 being involved in cellular processes Of the cellular components categories that were
enriched, with 174 upregulated genes being involved in the membrane.  In the top 30 enriched molecular
function categories, 232 genes were involved with binding, 163 had catalytic activity  and 93 were
involved with protein binding.
The Malpighian tubules had significant enrichment in biological processes with 708 genes being
expressed in the metabolic processes, 546 genes involving cellular metabolic processes and 118 being
involved in peptide biosynthetic processes.  In the cellular component category 492 genes were
intracellular, 334 genes were categorized as being in the cytoplasm, while 289 were categorized in
membrane bound organelles.  Molecular function enrichment revealed 576 genes being involved in
catalytic activity, and 467 genes were in the heterocyclic compound binding, and organic cyclic
compound binding categories (Supplementary Table 12).
In the brain, there was enrichment in metabolic processes with 763 genes, 672 genes were a part
of the organic substance metabolic process.  In the cellular components, 582 genes were intracellular, and
385 genes were membrane bound.  In the molecular function category, 1169 genes were involved in
binding, with 592 being organic cyclic compound binding (Supplementary Table 13).
Detoxification enzymes
Of the detoxification enzymes analyzed, 4 out of the 6 GSTs were differentially expressed
between tissues (Figure 7).  Of the 51 cytochrome p450s analyzed, 22 were differentially expressed
between tissues, with the majority being upregulated in the Malpighian tubules.  Lastly 5 out of 8
carboxylesterases analyzed were differentially expressed between tissues.  CYP6AS4 was the only P450
that was the most highly expressed in the brain, compared to the other tissues. Catalase was also the only
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enzyme that was the most highly expressed in the brain relative to the Malpighian tubules and the
ventriculus.  Lastly, Carboxylesterase clade I, member 1 was the only carboxylesterase that was the most
highly expressed in the brain. CYP18A1, CYP9Q1, and cytochrome p450 9-e2 like were the only P450s
that were up-regulated in the ventriculus relative to the brain and Malpighian tubules.  All the other
detoxification enzymes were up-regulated in the Malpighian tubules.
2.4 Discussion
The brain had the highest number of uniquely upregulated genes compared to the Malpighian
tubules and the ventriculus.  This makes sense seeing as the function of the brain is different compared to
the Malpighian tubules and ventriculus (both organs belonging to the digestive tract).  In terms of gene
enrichment, it was surprising to see that the Malpighian tubules and the brain had more molecular
functions in common compared to the ventriculus (Figure 7).  Many of these functions involved binding
of substrates such as cyclic molecules and a variety of nucleotides.  The Malpighian tubules are
responsible for the detoxification in the body, and much of that involves the breakdown of organic
molecules.  In the brain, these molecules (such as octopamine, dopamine etc.) are used to induce signals
between neurons.  So, though the MF functions may be similar, as shown in the BP categories, the
outcome of these functions is very different. KEGG analysis revealed that the Malpighian tubules are
enriched for metabolic processes, which is inline with its known role in filtering and detoxifying
substances from the hemolymph (Nocelli et al., 2016).
In terms of phase I detoxification, our data had the highest levels of CYP450 expression in the
Malpighian tubules followed by the ventriculus and brain having varying amounts of expression,
depending on the P450 (Figure 8).  This is interesting seeing as our data gives more insight into
understanding which P450 is more highly expressed in each tissue.  Decourtye et al., (2004) found that
CYP expression increased in the honeybee brain 30 minutes after a sublethal dose (0.12 ng) of
imidacloprid was fed.  However there was no follow-up study done to compare the levels 24 hours later.
While we weren’t able to get an unexposed/control tissue to determine the baseline levels of
detoxification enzymes, a honeybee protein atlas has been published which allows us to compare DEG
data (Chan et al., 2013).  When looking at the P450 expression, they found the highest expression in the
Malpighian tubules, followed by the brain, and then the ventriculus.  However it's important to note that
they had calculated the P450s as a fraction of all proteins across castes (workers tend to have higher P450
expression compared to queens and drones). When comparing organs in just the digestive tract (of bees of
mixed ages), Vannette et al. (2015), found a higher number of P450s to be expressed in the Malpighian
tubules, followed by high expression in the midgut, which is consistent with our findings.
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With regard to phase II detoxification, we found that GST expression was highest in the Malpighian
tubules, however the brain had higher Gst-1, Gst-U1, and Gst-T1 expression compared to the ventriculus
(figure 7). Higher phase II metabolism in the brain is also seen when comparing GST levels of the brain
to the Malpighian tubules as there was only a slight upregulation in Gst-U1 and GST-1 in the Malpighian
tubules (the detoxification center of the bee) compared to the brain.  Chan et al. (2013), found high GST
levels in the Malpghian tubules, ventriculus and the brain compared to the rest of the honeybee tissues in
the protein atlas. Because of the nature of their study, it wasn’t really clear which of the three tissues had
the most amount of GST expression, but they were higher compared to other honeybee tissues.  Vannette
et al. (2015) used qPCR to determine DEGs involved in detoxification in the honeybee digestive tracts
and found 4 GSTs were upregulated in the Malpighian tubules, while 5 were upregulated in the midgut.
Our data implies that there may be a downregulation in GST activity in the ventriculus, seeing as
we had lower levels compared to what has been published (Chan et al., 2013, Vanette et al., 2015).  This
could be a result of NNI damage to the ventriculus, similar to the effects seen by Oliveira et al., 2014.
This data also implies that the honeybee brain is more equipped to deal with NNI metabolites rather than
the original compounds.  This supports the idea that longer exposure to NNIs, even at sublethal doses,
becomes more toxic to bees.  As bees continue to ingest NNIs, first damage to their ventriculus is done
limiting their phase I detoxification (Oliveira et al., 2014, Catae et al., 2014).  Though their ventriculus
recovers in the long term (Catae et al., 2014), long term damage is done to the Malpighian tubules
(Oliveira et al., 2014) which have the highest phase I and phase II activity (based on their enzymes). Due
to the limited CYP expression in the brain, honeybees aren’t able to metabolize NNIs, or other exogenous
substances as efficiently leading to altered behaviour seen as a result of NNI exposure (Tvetkov et al.,
2017, Decourtye et al., 2004).
In terms of tissue specific expression of the CYP9 enzymes, the main NNI metabolizers, we found
that CYP9Q2 and CYP9Q3 was the most expressed in the Malpighian tubules compared to the other
tissues.  Once again this makes sense considering a major role of the Malpighian tubules is to detoxify
xenobiotic substances from the body.  Manjon et al. (2018) quantified CYP9Q baseline expression in the
brain, Malpighian tubules and ventriculus of honeybees using qPCR and found similar levels of CYP9Q1
in the midgut and the Malpighian tubules, while the brain had significantly low expression of CYP9Q1.
The midgut had the lowest expression of CYP9Q2, followed by a significant increase in the brain, while
the Malpighian tubules had the highest expression. CYP9Q3 expression levels were significantly higher
in the brain and Malpighian tubules compared to the midgut (Manjon et al., 2018). CYP9Q1 expression
patterns in our study were similar to Manjon et al. where the brain had the lowest expression followed by
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the MT and ventriculus.  CYP9Q2 was also significantly expressed in the Malpighian tubules relative to
the brain and ventriculus, however we did not see a difference between the brain and ventriculus. Manjon
et al. had found that the brain had similar CYP9Q3 expression levels as the Malpighian tubules, however
in our data, CYP9Q3 expression was significantly higher in the Malpighian tubules compared to the brain.
We also did not see a difference in CYP9Q3 expression between the brain and ventriculus, with the brain
only having a slight upregulation.As a result of clothianidin exposure in our study, the CYP9Q3 gene
could potentially be upregulated in the ventriculus and Malpighian tubules in all patrilines, however
because of the nature of our experiment, we have no negative control that could confirm this.  Looking at
the specific expression patterns of these enzymes allow us to see where the effects of NNI exposure could
have an impact.  Long term damage to the Malpighian tubules (Catae et al., 2014) would result in a
drastic reduction of clothianidin metabolism, seeing as that is where the CYP91-3 genes are the most
highly expressed.  The potential upregulation of CYP9Q3 in the ventriculus and Malpighian tubules
indicates that phase I metabolism of clothianidin does increase, and could help defend against the damage
that could be caused by short-term sublethal doses.
2.5 Conclusion
Our data provides insight into the detoxification mechanisms present in honeybee tissues, and
helps explain the long-term toxicity seen as a result of NNI field-realistic exposure on a molecular basis.
Damage to the ventriculus and Malpighian tubules can lead to altered phase I metabolism, making it
difficult for honeybees to break down NNIs, thus leading to long-term damage.  Additionally, looking at
the specific patterns of CYP9Q1-3 enzymes allow us to determine which tissues are the most susceptible
to NNI toxicity damage.  Follow up studies looking at longer-term detoxification enzyme expression in
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TABLES
Table 1: Summary of neonicotinoid resistant insects and their mechanisms based on a review done
by Bass et al., 2015
Species Upregulation (↑)/ Downregulation
(↓)/ mutation
Enzyme/gene





CYPCY3-caused by modification in
promoter region
β1 nAChR subunit –point mutation in
loop D region (R81T)
A Gasyppi mutation nAChR – R81T
N. Lugens mutation
↑
nAChR- N1α1 + N1α3
CYP6EA1, CYP6AY1
M. Domestica ↑ CYP6A1, CYP6D1, CYP6D3,
CYP6G4
T. vaporariorum ↑ CYP6CM1-4
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Table 2: Summary of LD50 trials of Patrilines being used in RNAseq analysis. Bees were fed a 29
ppb clothianidin-sugar solution for 1 hour. After 24 hours, bees were checked to see if they were dead or
alive, and survival rates based on Patrilines were determined. CYP9Q1 and CYP9Q3 genes were
sequenced and haplotype was determined,  Data provided by Nadia Tsvetkov.




P24 Alive 21 22 95 Resistant O C
P7 Alive 10 10 100 Resistant K C
P11 Alive 16 17 94 Resistant M C
P1 Alive 4 13 31 Non-Resistant N B
P8 Alive 5 13 38 Non-Resistant P E
P21 Alive 8 15 53 Non-Resistant L D
31




Figure 1: Overview of LD50 study (A) and RNA seq study design (B). Bees from the 3 patrilines who
exhibited the most resistance to the LD50 dose of clothianidin are being compared to bees from 3
patrilines who exhibited the least amount of resistance. The brains, Malpighian tubules, or ventriculus of
5 bees from each patriline will be pooled together. Each patriline represents a biological replicate for the
resistant/ non-resistant phenotype.
Figure 2: Honeybee tissues used in the transcriptomic analysis. RNA of the Brains (Br), Malpighian
tubules (Mal) and Ventriculus (V) of 5 bees exposed to 4.6 ppb of clothianidin were pooled for each
patriline.
34
Figure 3: RNA seq number of reads an alignment as determined by MultiQC. Reads were trimmed
using the Trimmomatic software before being aligned using STAR.  Average read length was 100 bp, and
average alignment was 99%.
35
Figure 4: PCA plots of the Malpighian tubules, Brain and Ventriculus of transcriptomic data of
honeybees exposed to 4.6 ppb of clothianidin.  Clustering based on resistance could only be seen in the
Malpighian tubules.
36
Figure 5: Significantly Enriched Biological Processes (blue) Molecular Function (red)  Gene
Ontology (GO) terms represented in the significantly upregulated DEGs in the Malpighian tubules
of non-resistant honeybees exposed to 4.6 ppb of clothianidin. A) Number of differentially expressed
genes associated with the GO process.  A total of 95 genes were found to be upregulated (p<0.05).
B) Hierarchical clustering of Enriched Molecular Function processes.
37
Figure 6: RNAseq data PCA of the Brain, Malpighian tubules and Ventriculus. Data clustered
strongly by organ
38
Figure 7:  Venn diagram of Enriched Biological Processes (BP), Cellular Compartments (CC),
Molecular Function (MF) and KEGG of uniquely upregulated genes in the Ventriculus (V)
Malipighian Tubules (MT) and the Brain (B) The Associated GO lists can be found in Supplementary
Tables !4-17
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Supplementary Table 1: List of DEGs in the Malpighian tubules between Resistant and non-resistant
patrilines exposed to a field realistic dose of clothianidin
Gene logFC logCPM PValue FDR GeneID Protein
XM_026445507.1 -4.30 4.43 4.6E-06 0.001 551562
dynein beta chain,
ciliary
XR_001703097.2 -4.24 2.67 2.2E-06 0.001 107964495
uncharacterized
LOC107964495
XM_392226.7 -3.84 -0.82 4.0E-04 0.040 408690 calmodulin






XM_006564738.3 -3.76 4.43 6.0E-09 0.000 412969
uncharacterized
LOC412969
XM_006559239.3 -3.49 -2.17 4.2E-06 0.001 724242 protein neuralized
XM_026444499.1 -3.29 -2.05 2.1E-04 0.025 410363
uncharacterized
LOC410363
XM_016912656.2 -3.16 -2.86 3.5E-06 0.001 408884
transcription factor
Sox-13




XR_001702612.2 -3.02 -0.54 4.3E-06 0.001 107964233
uncharacterized
LOC107964233
XM_016911272.2 -3.02 -0.81 2.5E-05 0.004 412883 Allatostatin C receptor
XM_394827.6 -2.99 7.97 4.1E-09 0.000 411353 lipase 3










XM_026440879.1 -2.81 8.20 2.8E-07 0.000 726309
LOC726309 protein
artichoke
XR_001703293.2 -2.81 -0.69 2.0E-05 0.004 107964569
uncharacterized
LOC107964569
XR_408967.3 -2.77 -2.44 1.1E-06 0.000 102656563
uncharacterized
LOC102656563
XM_006565484.3 -2.77 2.80 8.7E-07 0.000 551224 aminopeptidase N
XM_016913279.2 -2.75 4.58 3.9E-14 0.000 100578995 vanin-like protein 1
XM_016913467.2 -2.71 -1.00 2.6E-04 0.030 413052
uncharacterized
LOC413052




XM_006572315.3 -2.66 0.79 2.8E-04 0.032 100578112
adenylate kinase
isoenzyme 5
XM_006561437.3 -2.61 0.22 5.7E-09 0.000 408960
protein slit [ Apis
mellifera (honey bee) ]
XM_394067.6 -2.59 -1.38 2.1E-06 0.001 410589 semaphorin-5A
XM_026444698.1 -2.56 3.48 8.6E-08 0.000 408411
transcription factor
Sox-2
XR_003306397.1 -2.48 -0.98 1.4E-04 0.018 113219352
uncharacterized
LOC113219352
NM_001011636.1 -2.48 5.71 1.2E-07 0.000 409798 Fabp FABP-like protein
XM_003251822.4 -2.45 3.10 6.1E-09 0.000 100577161
uncharacterized
LOC100577161





XR_003306009.1 -2.44 -1.50 6.7E-08 0.000 107965414
uncharacterized
LOC107965414
XM_006557650.3 -2.43 -1.03 8.1E-07 0.000 102654685
uncharacterized
LOC102654685
XM_006565481.3 -2.40 10.48 2.6E-07 0.000 551180 aminopeptidase N
XM_026442484.1 -2.40 -0.44 1.3E-04 0.017 410791
mitochondrial
uncoupling protein 2




XM_006564914.3 -2.37 1.55 2.9E-04 0.032 552592
facilitated trehalose
transporter Tret1
XR_003306097.1 -2.33 3.00 1.2E-08 0.000 107965483
uncharacterized
LOC107965483
XM_393060.7 -2.29 2.85 2.8E-07 0.000 409553
pancreatic
triacylglycerol lipase




XM_003249136.4 -2.25 6.48 5.0E-04 0.049 100578100
uncharacterized
LOC100578100
NM_001013361.1 -2.24 3.81 1.8E-09 0.000 410902 18-w 18-wheeler
XM_026446208.1 -2.21 0.68 2.0E-04 0.023 412949 ionotropic receptor 25a









XM_003250107.4 -2.15 1.98 1.3E-05 0.003 100576163 short neuropeptide F
XM_003250921.4 -2.14 1.58 6.0E-07 0.000 100578548
uncharacterized
LOC100578548
XM_001120112.5 -2.13 9.86 1.9E-05 0.004 724308 serine protease 53
XM_026443683.1 -2.11 -0.56 1.2E-05 0.003 727052 mucin-17-like
XM_026439740.1 -2.10 -1.14 2.4E-07 0.000 100578706
uncharacterized
LOC100578706
XM_006559465.3 -2.09 0.57 3.0E-04 0.033 100577488
uncharacterized
LOC100577488
XM_623673.6 -2.09 5.10 1.7E-06 0.000 410729
putative serine protease
K12H4.7
XM_006561640.3 -2.07 1.15 5.1E-04 0.049 725671
homeobox protein
Nkx-2.8
XM_026442221.1 -2.03 1.49 3.3E-04 0.033 725670
mast/stem cell growth
factor receptor Kit
NM_001327967.1 -2.01 0.11 1.3E-05 0.003 724216
juvenile hormone acid
O-methyltransferase
XM_016910864.2 -2.01 -1.64 1.9E-06 0.001 408694 plastin-2
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XR_407492.3 -2.00 3.01 3.2E-04 0.033 100578394
uncharacterized
LOC100578394
XM_001121077.5 -1.98 7.88 1.6E-04 0.019 725202 chymotrypsin inhibitor










XM_003250751.4 -1.96 5.85 3.7E-07 0.000 100578731
uncharacterized
LOC100578731
XM_026444761.1 -1.95 3.08 3.4E-08 0.000 551796
cationic amino acid
transporter 4
XM_392630.6 -1.95 4.38 1.9E-11 0.000 408500
uncharacterized
LOC409105
XR_120331.4 -1.94 -0.78 2.8E-05 0.005 100576585
uncharacterized
LOC100576585
XM_394855.6 -1.91 7.48 1.3E-04 0.017 411381
Apis mellifera
caspase-3




XR_119746.4 -1.88 1.72 1.3E-06 0.000 100576397
uncharacterized
LOC100576397
XR_003305949.1 -1.83 0.07 1.4E-05 0.003 113219194
uncharacterized
LOC113219194
XM_001121102.5 -1.83 1.93 4.0E-04 0.040 725225 ninjurin-2
XR_001705202.1 -1.83 0.13 2.7E-04 0.031 107965347
uncharacterized
LOC107965347
XM_006561800.3 -1.80 7.25 1.6E-05 0.003 726818
beta-hexosaminidase
subunit beta
XM_016914797.2 -1.79 8.19 2.2E-05 0.004 408320
uncharacterized
LOC408320








XM_026444640.1 -1.77 4.59 8.3E-07 0.000 107965746
uncharacterized
LOC107965746
XM_001121910.4 -1.71 -0.48 1.3E-04 0.017 726150
transcription factor
Sox-21-B
XM_016916502.2 -1.71 6.98 8.4E-05 0.012 408534 Apis mellifera trypsin





XM_006566014.3 -1.69 2.67 1.7E-05 0.003 410211
four and a half LIM
domains protein 2
XM_026442934.1 -1.68 -1.52 3.2E-05 0.005 113218571
hydrocephalus-inducin
g protein-like
XM_006560978.3 -1.66 -0.52 2.4E-04 0.028 412774
uncharacterized
LOC412774
XM_026442948.1 -1.65 5.79 3.2E-04 0.033 409465
uncharacterized
LOC409465








XM_006562350.3 -1.60 0.00 1.4E-04 0.018 409057
uncharacterized
LOC409057




XM_003249633.4 -1.58 5.41 2.4E-07 0.000 100578090
uncharacterized
LOC100578090
XM_395905.6 -1.54 3.82 3.2E-06 0.001 412448 zinc transporter ZIP1
XM_016917454.2 -1.50 4.91 1.3E-06 0.000 412316
sodium/potassium/calci
um exchanger 3
XM_026442378.1 -1.48 5.19 1.3E-04 0.017 726315
sphingomyelin
phosphodiesterase 1
XM_026444746.1 -1.47 3.98 1.4E-04 0.018 107965400
probable cytochrome
P450 6a14





XR_001702082.2 -1.28 3.27 1.7E-05 0.003 107964028
uncharacterized
LOC107964028




XM_026439095.1 -1.26 5.44 6.0E-06 0.001 408661
uncharacterized
LOC408661
XM_003249567.4 -1.24 5.21 9.0E-08 0.000 100578068
lateral signaling target
protein 2 homolog















Survival mean FC Probability GeneID Protein




XM_001120613.5 4600 18827 -2.03 0.985 724721
farnesol
dehydrogenase




XM_394018.7 3948 15211 -1.95 0.978 410539 protein 5NUC
XM_016913496.2 2358.5 8677 -1.88 0.956 107964838
probable uridine
nucleosidase 2
NM_001011583.2 30909.5 113604 -1.88 0.997 406094
chemosensory
protein 3
NM_001011598.1 31466 114680 -1.87 0.997 406114 alpha-amylase





XM_392401.7 22253 79930 -1.84 0.996 408871
sorbitol
dehydrogenase
XM_001120801.4 10941 39273 -1.84 0.992 726860 cytochrome b5















XM_001121061.5 2885 9712 -1.75 0.960 726978
homeodomain-onl
y protein
XM_003249082.4 3073.5 10073 -1.71 0.961 100578929
uncharacterized
LOC100578929




XM_026442250.1 7982 24659 -1.63 0.986 412694
uncharacterized
LOC412694





XM_026441700.1 9872 28329 -1.52 0.986 725936 titin homolog
XM_016914951.2 11746 31306 -1.41 0.986 727593
UDP-glucuronosyl
transferase 2C1
XM_392446.7 5313 14137 -1.41 0.969 408918
death-associated
protein 1








XM_006564945.3 16123 41186 -1.35 0.988 724293 yellow-x1




XM_392591.7 5860 14457 -1.30 0.966 409066
pyridoxine-5'-phos
phate oxidase
XM_003250766.4 13743.5 30990 -1.17 0.981 726268
uncharacterized
LOC726268




XM_003249259.4 17072.5 38267 -1.16 0.983 100578226
zinc finger protein
GLI1




XM_006557449.3 8820 17677 -1.00 0.958 102654369
la-related protein
6






XM_016911661.2 30796 58434 -0.92 0.970 408818 hexokinase-1
XM_026443298.1 26066 48708 -0.90 0.967 412458
farnesol
dehydrogenase
XM_624343.6 28387 51600 -0.86 0.962 551961
V-type proton
ATPase subunit G
XM_625095.6 26867 48248 -0.84 0.958 552720
V-type proton
ATPase subunit E
XM_624109.5 53663.5 95311 -0.83 0.959 551721
V-type proton
ATPase subunit B
XM_003249180.4 49640 28363 0.81 0.951 726804 protein BTG2
XM_006572061.3 46117.5 26120 0.82 0.952 725680
vesicle-fusing
ATPase 1




XM_006572019.3 33461.5 18883 0.83 0.950 412245
acidic mammalian
chitinase
XM_006559974.3 172585.5 96676 0.84 0.964 408547 toxin 3FTx-Lei1
XM_392359.7 36510.5 20399 0.84 0.954 408827
carbonic
anhydrase 1
NM_001011635.1 156665 87509 0.84 0.964 409376 yellow-f




XM_392611.7 67106.5 37108 0.85 0.961 409086 caprin homolog
XR_001704393.2 40387 21724 0.89 0.963 107965036
uncharacterized
LOC107965036
XM_623217.6 65468 35027 0.90 0.968 550827
tubulin alpha-1
chain









XM_395236.7 60474.5 31969 0.92 0.970 411769
kinesin heavy
chain




XM_026443772.1 23805.5 12498 0.93 0.957 551941
uncharacterized
LOC551941
NM_001256037.1 30930 16180 0.93 0.964 727274
PHD and ring
finger domains 1
XM_392313.7 171625 89649 0.94 0.977 408782 tubulin beta-1
XM_393699.7 23446.5 12198 0.94 0.958 410216 reticulocalbin-2
XM_623210.6 41466 21541 0.94 0.969 408971
ras-related protein
Rab-3
XM_026442948.1 19827 10285 0.95 0.955 409465
uncharacterized
LOC409465




NM_001278330.1 42051.5 21757 0.95 0.971 726003 Rab escort protein
XM_392799.7 100719.5 52079 0.95 0.977 409278 apolipoprotein D
XM_026439176.1 51703.5 26609 0.96 0.974 551687
uncharacterized
LOC551687




XM_016914717.2 24685.5 12617 0.97 0.963 107965147
uncharacterized
LOC107965147
XM_393267.7 57454.5 29317 0.97 0.975 409774 proteoglycan Cow
XM_392759.7 52130.5 26562 0.97 0.974 409235 neurotrimin




XM_006565857.3 106120.5 53892 0.98 0.979 726924
synapse-associate
d protein 1
XM_006562570.3 25887 13135 0.98 0.965 409212 cadherin-87A
50
XM_026442738.1 104800.5 52915 0.99 0.980 409020 inaD-like protein
XM_001119962.5 63931 32273 0.99 0.977 724192 titin





XM_625067.6 20636 10392 0.99 0.959 552693
uncharacterized
LOC552693
XM_026441761.1 22347.5 11220 0.99 0.963 107963990 mucin-5AC
XM_026446479.1 37484.5 18788 1.00 0.974 409034
uncharacterized
LOC409034




XM_006569936.3 23200.5 11590 1.00 0.965 100576346 protein PFC0760c
XM_026439652.1 55715 27788 1.00 0.978 408725 protein sickie
XM_001121323.5 18550.5 9245 1.00 0.959 725480 innexin inx1
XM_396806.6 18282 9111 1.00 0.958 413361
TBC1 domain
family member 16
XR_003305294.1 19101 9514 1.01 0.961 113218980
uncharacterized
LOC113218980
XM_003250216.4 55016.5 27199 1.02 0.980 100576569
uncharacterized
LOC100576569
XM_395173.7 14570.5 7202 1.02 0.953 411705 synaptojanin-1




XM_003249827.4 14506 7124 1.03 0.954 100576471
uncharacterized
LOC100576471





XM_001121525.5 29905.5 14614 1.03 0.974 725708
uncharacterized
LOC725708
XM_001122027.5 13905 6766 1.04 0.952 726276
uncharacterized
LOC726276




XR_003305570.1 24096 11701 1.04 0.970 494508
serine/threonine-p
rotein kinase pakE
XM_392602.7 964759.5 468453 1.04 0.987 409077 aminopeptidase N
XM_393174.7 23797 11531 1.05 0.970 409676 kinesin 2A
XM_001121946.5 21935 10617 1.05 0.967 726190
arginine/serine-ric
h protein PNISR
XM_001123131.5 20772 10017 1.05 0.965 727423
uncharacterized
LOC727423
XM_392231.7 268748.5 129225 1.06 0.987 408695
uncharacterized
LOC408695












XM_001120658.5 34230 16385 1.06 0.977 724761
uncharacterized
LOC724761
XM_394578.6 17371 8289 1.07 0.962 411104
homeobox protein
Nkx-2.4





XM_016916593.2 352153 166884 1.08 0.988 102656354
uncharacterized
LOC102656354
XM_026444509.1 13622.5 6449 1.08 0.954 409539
microtubule-assoc
iated protein 2
XM_026445497.1 25952 12268 1.08 0.973 413784 rabphilin
XM_006568615.3 17580 8299 1.08 0.962 725150
uncharacterized
LOC725150
XM_006567389.3 95621 45115 1.08 0.985 408987
sortilin-related
receptor





XM_006564472.3 15173 7111 1.09 0.958 100578890
uncharacterized
LOC100578890





XM_026440223.1 13999.5 6546 1.10 0.956 411209
uncharacterized
LOC411209
XM_026442495.1 39065 18212 1.10 0.980 100578826
protein strawberry
notch-like




XM_006561263.3 13059.5 6043 1.11 0.953 551658 anillin
XM_026444930.1 45132 20771 1.12 0.983 726997
uncharacterized
LOC726997
XM_393631.7 15415 7090 1.12 0.961 410148
carboxypeptidase
Q









XM_392256.7 27412 12413 1.14 0.977 408721
neurocalcin
homolog





NM_001012962.1 21079 9502 1.15 0.972 503861
nitric oxide
synthase
XM_006561241.3 23317 10508 1.15 0.975 550870
uncharacterized
LOC550870
XM_006562299.3 38701.5 17413 1.15 0.983 552017 alpha-catulin
XM_026441982.1 13052 5867 1.15 0.957 409624
acetyl-coenzyme
A synthetase























XM_026440829.1 63637 28459 1.16 0.986 726101
uncharacterized
LOC726101




XM_006558996.3 43322 19353 1.16 0.984 409323
uncharacterized
LOC409323




XM_006559821.3 111481 48793 1.19 0.990 408951
14-3-3 protein
epsilon
XM_026440032.1 13292.5 5806 1.19 0.960 406139 ankyrin-3
XM_392630.6 18648 8141 1.20 0.970 409105
uncharacterized
LOC409105
XM_006570090.3 12945 5593 1.21 0.959 551031
uncharacterized
LOC551031
XM_006566860.3 15669 6752 1.21 0.966 410379
uncharacterized
LOC410379
XM_393966.5 26443.5 11389 1.22 0.980 410487
uncharacterized
LOC410487
XM_026440227.1 48156 20584 1.23 0.987 408797 nidogen-2








NM_001011565.1 11821.5 5042 1.23 0.955 406068
octopamine
receptor




XM_026439113.1 165979.5 70069 1.24 0.992 102655100
protein Cep78
homolog
XM_006561089.3 134002.5 56462 1.25 0.992 552020 neuromodulin
XM_392431.5 53847.5 22534 1.26 0.988 408902
F-box/LRR-repeat
protein 16
XM_394464.7 12972.5 5426 1.26 0.961 410989 menin
XM_006566073.3 112065 46767 1.26 0.992 100576882
uncharacterized
LOC100576882
XM_026446329.1 12176 5078 1.26 0.958 100577959
uncharacterized
LOC100577959
XM_026439116.1 11856.5 4941 1.26 0.957 725294
tyrosine-protein
phosphatase 99A









NM_001172718.1 39222.5 16239 1.27 0.986 100379261
uncharacterized
LOC100379261
XM_396815.6 19449.5 8026 1.28 0.974 413370 hemicentin-2
XM_393156.7 13752 5671 1.28 0.964 409658
uncharacterized
LOC409658
XM_006561834.3 35306.5 14554 1.28 0.985 409004
ras-related protein
Rab6









XM_624701.6 191434 77942 1.30 0.993 552326
uncharacterized
LOC552326
XR_003304346.1 45280.5 18363 1.30 0.987 113218632
uncharacterized
LOC113218632
XM_026444693.1 10678 4320 1.31 0.952 408408
uncharacterized
LOC408408
XM_001120296.5 27317.5 11035 1.31 0.982 724439
uncharacterized
LOC724439
XM_026439426.1 11318.5 4559 1.31 0.956 410918
protein tramtrack,
beta isoform
XM_397519.7 163461.5 65791 1.31 0.993 408696
uncharacterized
LOC408696





XM_016916296.2 10651.5 4248 1.33 0.952 411617
inactive rhomboid
protein 1




XM_006559511.3 13503 5333 1.34 0.964 552576
activated Cdc42
kinase-like
XM_006569316.3 76190 30060 1.34 0.991 409949 agrin
NM_001160064.1 355547.5 139813 1.35 0.994 408928
heat shock protein
90
XM_001120452.5 22136.5 8690 1.35 0.979 724563
uncharacterized
LOC724563















XM_026439677.1 26090.5 10107 1.37 0.983 113218647
gamma-aminobuty
ric acid type B
receptor subunit 1
XM_001119931.5 29554 11382 1.38 0.984 724178
uncharacterized
LOC724178
XM_006562668.3 123933.5 47681 1.38 0.993 408809
diacylglycerol
kinase theta




XR_001706525.2 165934 63298 1.39 0.994 107966103
uncharacterized
LOC107966103





XM_006560749.3 13499.5 5135 1.39 0.966 409022 fruitless
XM_006564049.3 106170 40252 1.40 0.993 410467
uncharacterized
LOC410467
XM_026445233.1 30607.5 11584 1.40 0.986 100576461
uncharacterized
LOC100576461
XM_003251160.4 37496 14132 1.41 0.988 724220 synaptotagmin-10




XM_006566196.3 128085.5 48213 1.41 0.994 726321
uncharacterized
LOC726321




XR_003306559.1 16852 6320 1.41 0.973 102654200
uncharacterized
LOC102654200
XM_001121838.5 28121.5 10509 1.42 0.985 726068
uncharacterized
LOC726068
XM_393712.6 12135.5 4534 1.42 0.963 410229 toll-like receptor 6
XM_026443706.1 154285 57449 1.43 0.995 413428
uncharacterized
LOC413428


















XM_026440031.1 61533.5 22195 1.47 0.992 409981 titin
XM_001122204.5 53487 19289 1.47 0.990 726472 prohormone-3
XM_001121746.5 840891 303139 1.47 0.996 725960
neurofilament
heavy polypeptide
XM_026444761.1 16909.5 6077 1.48 0.974 551796
cationic amino
acid transporter 4




































XM_392545.7 34594.5 12065 1.52 0.989 409016
uncharacterized
LOC409016
XM_026442500.1 301095 104778 1.52 0.996 408961 apolipophorins

















XM_392366.7 78340.5 26805 1.55 0.994 408835
neuroendocrine
convertase 2
NM_001256040.1 123774.5 42156 1.55 0.995 100859932
uncharacterized
LOC100859932




XM_026445737.1 17269.5 5834 1.57 0.977 552490
uncharacterized
LOC552490
XM_016911769.2 9515.5 3195 1.57 0.954 102654965
uncharacterized
LOC102654965




XM_026440891.1 14609.5 4882 1.58 0.972 102654994
uncharacterized
LOC102654994
XM_006561070.3 20797.5 6939 1.58 0.982 409781
uncharacterized
LOC409781





XM_016911303.2 12483 4156 1.59 0.968 107964189
uncharacterized
LOC107964189
NM_001327949.1 13788.5 4582 1.59 0.971 100577273
uncharacterized
LOC100577273




















NM_001145740.1 10451.5 3427 1.61 0.961 724217 neurexin 1
XM_026439692.1 11475.5 3759 1.61 0.965 726283
neuronal calcium
sensor 2
XM_393772.6 13552.5 4376 1.63 0.971 410291 dipeptidase 1
XM_003249754.4 18037 5798 1.64 0.980 100578822
protein IWS1
homolog
NM_001011636.1 81200.5 25912 1.65 0.995 409798 FABP-like protein
XM_026440916.1 49613 15770 1.65 0.992 408865
uncharacterized
LOC408865
XM_016915816.2 10715.5 3401 1.66 0.964 410689
ELAV-like protein
2
XM_006563127.3 48166.5 15240 1.66 0.992 408554 neural-cadherin





NM_001167836.1 17316.5 5401 1.68 0.979 409314 prohormone-2




NM_001040230.1 193270.5 60172 1.68 0.997 406104
acetylcholinestera
se 2
XM_026445881.1 78834.5 24261 1.70 0.995 100577769
uncharacterized
LOC100577769
XM_397501.6 15420.5 4690 1.72 0.975 408473
uncharacterized
LOC408473
XR_003304193.1 168209 51148 1.72 0.997 113218601
uncharacterized
LOC113218601




XM_026440863.1 30123.5 9145 1.72 0.990 551385 frequenin-1








XM_394423.7 9522 2881 1.72 0.957 410947
tyrosine
decarboxylase









XR_003305178.1 17667 5243 1.75 0.980 113218944
uncharacterized
LOC113218944
XM_026441660.1 11956 3525 1.76 0.969 100576948
GTP-binding
protein RAD-like
XM_392530.7 10151 2745 1.89 0.965 409000
cell adhesion
molecule 2
XM_006558502.3 9423 2405 1.97 0.962 552578
uncharacterized
LOC552578
XM_001120327.5 9391 2363 1.99 0.962 724465
enhancer of split
mbeta protein
XM_396310.6 10506 2596 2.02 0.967 412858 hemicentin-2




XM_026440983.1 29784 7116 2.07 0.991 100576683
uncharacterized
LOC100576683
XM_006558575.3 25775 5678 2.18 0.990 113218523
uncharacterized
LOC113218523
XR_003305923.1 14912.5 3233 2.21 0.979 113219182
uncharacterized
LOC113219182
XM_006562260.3 24663 3820 2.69 0.990 410368 cadherin-23
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mean FC Probability GeneID Protein
NM_001011572.1 14284.5 58093 -2.02 0.983 406078 transferrin 1




XM_001120296.5 6778.5 20288 -1.58 0.960 724439
uncharacterized
LOC724439
XM_001121746.5 22374 90525 -2.02 0.986 725960
neurofilament
heavy polypeptide




XM_003250091.4 41061.5 11028 1.90 0.979 100577527
uncharacterized
LOC100577527
XM_006559813.3 49006.5 18512 1.40 0.968 102655332 protein orai-2




XM_006562300.3 180160 70644 1.35 0.974 408453
cytochrome P450
9e2
XM_006562785.3 176859.5 88071 1.01 0.951 726592 proteoglycan 4














XM_006570570.3 101904.5 18914 2.43 0.990 102654405
uncharacterized
LOC102654405

















XM_026438943.1 56810.5 25516 1.15 0.955 100577377
uncharacterized
LOC100577377
XM_026439113.1 5934.5 22522 -1.92 0.972 102655100
protein Cep78
homolog
XM_392319.7 69016.5 25937 1.41 0.971 408788
UDP-glucuronosy
ltransferase 1-3
XM_392799.7 3767 15222 -2.01 0.962 409278 apolipoprotein D
XM_394092.7 257960.5 128238 1.01 0.953 410614
tubulin alpha
chain
XM_394370.5 110695.5 33979 1.70 0.982 410894 chymotrypsin-1
XM_394827.6 59086.5 28120 1.07 0.951 411353 lipase 3





XM_623724.5 48967 17129 1.52 0.972 551327
carboxypeptidase
B
XM_623919.5 58711 25773 1.19 0.959 551524
zinc
carboxypeptidase
XR_001706525.2 5593 21471 -1.94 0.971 107966103
uncharacterized
LOC107966103











Survival mean FC Probability GeneID Protein
NM_001011579.1 47 8786 -7.55 0.984 406090
major royal jelly
protein 1
NM_001011578.1 5308.5 361 3.88 0.969 406088 vitellogenin
XM_006570574.












Mean FC Probability GeneID Protein
Brain NM_001011598.1 12517 56680.33333 -2.18 0.987 406114 alpha-amylase







NM_001011640.1 2640 12092 -2.20 0.972
449496 take-out-like
carrier protein











XM_001119981.5 178229 71441 1.32 0.964
724211 cytochrome
P450 9e2
XM_006562300.3 41401 15620 1.41 0.964
408453 cytochrome
P450 9e2
NM_001160064.1 50816 20152 1.33 0.960
408928 heat shock
protein 90
XM_026442500.1 20236 8023 1.33 0.953 408961 apolipophorins
Malpighian
Tubules
NM_001011607.2 719 16816 -4.55 0.982 406130 melittin
NM_001011636.1 13869 1593.333333 3.12 0.971 409798
FABP-like
protein
NM_001110764.1 8715 28616 -1.72 0.950 726848 hexamerin 70a
NM_001160064.1 43680 13427.66667 1.70 0.952 408928
heat shock
protein 90




XM_001121077.5 31581 9410.666667 1.75 0.952 725202
chymotrypsin
inhibitor













XM_006562300.3 70644 305785.3333 -2.11 0.971 408453
cytochrome
P450 9e2
XM_006565481.3 216107 45502.66667 2.25 0.974 551180
aminopeptidas
e N





















XM_026440879.1 50443 7240 2.80 0.980 726309
protein
artichoke
XM_026442948.1 12992 2719 2.26 0.956 409465
uncharacterize
d LOC409465









XM_393127.6 237939 30475.66667 2.96 0.987 409626
chymotrypsin-
2




XM_394827.6 28120 5688 2.31 0.967 411353 lipase 3





















NM_001011607.2 1149.5 16816 -3.87 0.979 406130 melittin












67 1.77 0.962 551524
zinc
carboxypeptidase
XM_001120425.5 43715 12500 1.81 0.962 724536
uncharacterized
LOC724536





33 1.99 0.962 408534 trypsin
XM_016914797.2 53913 13325 2.02 0.969 408320
uncharacterized
LOC408320
XM_623724.5 48967 12074 2.02 0.968 551327 carboxypeptidase B















67 2.23 0.970 411381 caspase-3
XM_003250751.4 11475.5
2420.6666















33 2.45 0.982 724308 serine protease 53
XM_026439414.1 18790
3180.6666









67 2.63 0.985 551180 aminopeptidase N




XM_026440879.1 60616 7240 3.07 0.986 726309 protein artichoke
XM_393127.6 284252
30475.666
67 3.22 0.991 409626 chymotrypsin-2
XM_001120116.5 39394.5 4214 3.22 0.984 724312 vanin-like protein 1
XM_394827.6 59086.5 5688 3.38 0.987 411353 lipase 3
XM_026445507.1 6060
204.33333




XM_001120296.5 9511.5 1948 2.29 0.970
724439 uncharacterized
LOC724439








Supplementary Table 7:  Enriched GO processes of Upregulated genes in the brain of the Intermediate
Survival group compared when compared to the Low Survival group
GO Category Functional Category
Enrichment
FDR Genes in list
Biological Processes Small molecule metabolic process 0.002 7
Pyridine-containing compound metabolic process 0.002 3
Small molecule biosynthetic process 0.002 4
Cellular aldehyde metabolic process 0.002 2
Transmembrane transport 0.002 7
Cation transmembrane transport 0.002 4
Inorganic ion transmembrane transport 0.002 4
Inorganic cation transmembrane transport 0.002 4
Proton transmembrane transport 0.002 3
Nucleoside phosphate metabolic process 0.002 4
Nucleotide metabolic process 0.002 4
Monovalent inorganic cation transport 0.002 4
Organophosphate metabolic process 0.002 5
Monocarboxylic acid metabolic process 0.002 3
Establishment of localization 0.002 8
Nucleobase-containing small molecule metabolic
process 0.002 4
Oxidation-reduction process 0.002 6
ATP hydrolysis coupled transmembrane transport 0.002 2
ATP hydrolysis coupled ion transmembrane transport 0.002 2
Coenzyme metabolic process 0.002 3
Transport 0.002 8
Cation transport 0.002 4
Energy coupled proton transmembrane transport,
against electrochemical gradient 0.002 2
ATP hydrolysis coupled proton transport 0.002 2
Localization 0.003 8
Nucleotide catabolic process 0.003 2
Nucleoside phosphate catabolic process 0.004 2
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Ribose phosphate metabolic process 0.004 3
Pyridine-containing compound biosynthetic process 0.004 2
Ion transmembrane transport 0.005 4
Cellular Components Proton-transporting two-sector ATPase complex 0.001 3
Proton-transporting two-sector ATPase complex,
catalytic domain 0.003 2
Proton-transporting V-type ATPase complex 0.003 2
Membrane 0.020 13
Membrane part 0.020 13
Membrane protein complex 0.020 3
Molecular Function Cofactor binding 0.000 8
Primary active transmembrane transporter activity 0.000 4
P-P-bond-hydrolysis-driven transmembrane transporter
activity 0.000 4
ATPase activity, coupled to transmembrane movement
of substances 0.000 4
ATPase activity, coupled to movement of substances 0.000 4
Ion binding 0.000 15
Coenzyme binding 0.000 5
ATPase activity, coupled 0.000 4
Active transmembrane transporter activity 0.000 4
Organic cyclic compound binding 0.000 15
Heterocyclic compound binding 0.000 15
Catalytic activity 0.000 16
Small molecule binding 0.000 10
Nucleotide binding 0.001 9
ATPase activity 0.001 4
Nucleoside phosphate binding 0.001 9
Oxidoreductase activity 0.001 6
Anion binding 0.001 9
Heme binding 0.002 3
Tetrapyrrole binding 0.002 3
Transmembrane transporter activity 0.004 5
Transporter activity 0.007 5
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Carbohydrate derivative binding 0.009 7
Binding 0.011 18
Cation binding 0.011 7
Monooxygenase activity 0.013 2
Nucleoside-triphosphatase activity 0.015 4
Pyrophosphatase activity 0.015 4
Oxidoreductase activity, acting on CH-OH group of
donors 0.015 2
Hydrolase activity, acting on acid anhydrides 0.015 4
KEGG Metabolic pathways 0.000 8
Phagosome 0.000 3
MTOR signaling pathway 0.000 3
Oxidative phosphorylation 0.001 3
Peroxisome 0.004 2
Carbon metabolism 0.008 2
Supplementary Table 8:   Enriched GO processes of Upregulated genes in the brain of the Low Survival
group when compared to the Intermediate Survival group
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GO Category Functional Category
Enrichment
FDR Genes in list
Biological Processes
Regulation of vesicle-mediated transport 0.006 3
Establishment of localization 0.008 24
Transport 0.008 24
Localization 0.009 24
Cell-cell adhesion via plasma-membrane adhesion
molecules 0.027 3
Phosphorus metabolic process 0.027 17
Phosphate-containing compound metabolic process 0.027 17
Homophilic cell adhesion via plasma membrane
adhesion molecules 0.027 3
Regulation of exocytosis 0.027 2
Regulation of secretion 0.030 2
Cell-cell adhesion 0.030 3
Regulation of secretion by cell 0.030 2
Potassium ion transport 0.030 4
Dephosphorylation 0.030 6
Phospholipid dephosphorylation 0.034 2
Phosphatidylinositol dephosphorylation 0.034 2
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Cell adhesion 0.034 4
Biological adhesion 0.034 4
Response to drug 0.041 2
Regulation of transport 0.044 3
Regulation of molecular function 0.050 7
Cellular Processes Microtubule 0.000 6
Intrinsic component of plasma membrane 0.000 6
Supramolecular complex 0.000 6
Supramolecular polymer 0.000 6
Supramolecular fiber 0.000 6
Polymeric cytoskeletal fiber 0.000 6
Integral component of plasma membrane 0.001 5
Sodium:potassium-exchanging ATPase complex 0.002 2
Plasma membrane part 0.002 6
Cation-transporting ATPase complex 0.002 2
Plasma membrane 0.002 10
Membrane 0.002 52
Intrinsic component of membrane 0.002 49
Cell periphery 0.002 10
Membrane part 0.003 50
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Microtubule cytoskeleton 0.003 6
ATPase dependent transmembrane transport complex 0.005 2
Integral component of membrane 0.006 47
Cytoskeleton 0.009 7
Cytoskeletal part 0.011 6
Anchored component of membrane 0.021 2
Molecular Function Binding 0.019 77
Calcium ion binding 0.019 8
Phosphoric ester hydrolase activity 0.019 7
Ion binding 0.019 41
Nucleotide binding 0.022 23
Transporter activity 0.022 14
Hydrolase activity 0.022 25
Hydrolase activity, acting on ester bonds 0.022 10
Enzyme regulator activity 0.022 6
Ribonucleotide binding 0.022 21
Small molecule binding 0.022 24
Carbohydrate derivative binding 0.022 22
Nucleoside phosphate binding 0.022 23
76
Lipid transporter activity 0.022 3
Cytoskeletal protein binding 0.023 7
Purine nucleotide binding 0.027 20
Active transmembrane transporter activity 0.027 5
Purine ribonucleotide binding 0.027 20
Cation binding 0.027 22
Phosphatase activity 0.029 5
Calmodulin binding 0.030 2
Dipeptidase activity 0.030 2
Lyase activity 0.030 5
Protein binding 0.031 33
Guanylate cyclase activity 0.033 2
Anion binding 0.033 22
Rab GTPase binding 0.034 2
Metal ion binding 0.034 21
Molecular function regulator 0.034 7
Purine nucleoside binding 0.040 6
KEGG
Longevity regulating pathway 0.013 3
Phagosome 0.047 3
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Supplementary Table 9:  Enriched GO processes of upregulated genes in the Malpighian tubules of Low
Survival group when compared to the Intermediate Survival group
GO Category Functional Category
Enrichment
FDR Genes in list
Biological Process Proteolysis 0.013 4
Molecular Function Proteolysis 0.013 4
Metallocarboxypeptidase activity 0.002 2
Carboxypeptidase activity 0.002 2
Peptidase activity 0.002 4
Metalloexopeptidase activity 0.002 2
Hydrolase activity 0.002 7
Peptidase activity, acting on L-amino acid peptides 0.002 4
Exopeptidase activity 0.007 2
Catalytic activity 0.012 9
Serine-type endopeptidase activity 0.012 2
Serine-type peptidase activity 0.014 2
Serine hydrolase activity 0.014 2
Metallopeptidase activity 0.014 2
Transition metal ion binding 0.023 3
Catalytic activity, acting on a protein 0.023 4
Transmembrane transporter activity 0.025 3
Endopeptidase activity 0.028 2
Transporter activity 0.030 3
78
Supplementary Table 10:   Enriched GO processes of upregulated genes in the Malpighian tubules of Low
Survival group when compared to the High Survival group
GO Category Functional Category
Enrichment
FDR Genes in list
Biological Processes Proteolysis 0.000 7
Protein metabolic process 0.000 8
Organonitrogen compound metabolic process 0.001 8
Primary metabolic process 0.002 10
Organic substance metabolic process 0.002 10
Metabolic process 0.002 11
Nitrogen compound metabolic process 0.003 9
Macromolecule metabolic process 0.006 8
Molecular Function Peptidase activity 0.000 7
Hydrolase activity 0.000 11
Peptidase activity, acting on L-amino acid peptides 0.000 7
Catalytic activity, acting on a protein 0.000 8
Catalytic activity 0.000 12
Exopeptidase activity 0.000 3
Endopeptidase activity 0.000 4
Metallocarboxypeptidase activity 0.000 2
Serine-type endopeptidase activity 0.001 3
Carboxypeptidase activity 0.001 2
Serine-type peptidase activity 0.001 3
Serine hydrolase activity 0.001 3
Metallopeptidase activity 0.001 3
Metalloexopeptidase activity 0.001 2
Zinc ion binding 0.015 3
Transition metal ion binding 0.033 3
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Supplementary Table 11:  Enriched GO processes of uniquely upregulated genes in the Ventriculus
GO Category Functional Category
Enrichment
FDR Genes in list
Biological
Processes Metabolic process 1E-08 204
Establishment of localization 3E-06 71
Organic substance metabolic process 3E-06 168
Transport 3E-06 71
Localization 5E-06 71
Primary metabolic process 1E-05 158
Organonitrogen compound metabolic process 1E-05 101
Nitrogen compound metabolic process 1E-05 147
Protein metabolic process 2E-05 85
Macromolecule metabolic process 3E-05 133
Proteolysis 2E-04 34
Cellular process 7E-04 196
Ion transport 7E-03 26
Transmembrane transport 9E-03 37
Dephosphorylation 1E-02 13
Biological regulation 1E-02 87
Cellular metabolic process 2E-02 133
Macromolecule modification 3E-02 47
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Regulation of cellular process 4E-02 77
Regulation of biological process 4E-02 79
Cellular
Components Integral component of membrane 5E-08 167
Intrinsic component of membrane 5E-08 167
Membrane part 9E-08 170
Membrane 2E-07 174
Nucleosome 2E-04 8
Protein-DNA complex 2E-04 8
DNA packaging complex 4E-04 8
Endomembrane system 7E-03 20
Chromatin 9E-03 8
Cell 1E-02 127
Chromosomal part 2E-02 10
Intracellular part 2E-02 102
Intracellular 3E-02 110
Golgi cisterna 3E-02 3
Golgi cisterna membrane 3E-02 3
Organelle 3E-02 87
Cytoplasm 3E-02 52
Cell part 3E-02 121
Golgi stack 3E-02 3
Intracellular organelle 3E-02 85
Chromosome 3E-02 10
Endoplasmic reticulum 4E-02 9
Actin cytoskeleton 4E-02 6
81
Non-membrane-bounded organelle 4E-02 28
Intracellular non-membrane-bounded organelle 4E-02 28
Bounding membrane of organelle 4E-02 10
Peptidase complex 4E-02 5
Organelle subcompartment 4E-02 11
Membrane-bounded organelle 5E-02 69
COPII vesicle coat 5E-02 2
Molecular
Function Catalytic activity 2E-05 163
Hydrolase activity 2E-05 81
Peptidase activity 5E-05 31
Peptidase activity, acting on L-amino acid peptides 5E-05 30
Catalytic activity, acting on a protein 7E-05 57
Hydrolase activity, hydrolyzing O-glycosyl compounds 1E-03 10
Transporter activity 2E-03 37
Transmembrane transporter activity 2E-03 34
Cysteine-type peptidase activity 3E-03 10
Binding 4E-03 232
Hydrolase activity, acting on glycosyl bonds 4E-03 10
Protein heterodimerization activity 4E-03 8
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Endopeptidase activity 4E-03 17
Serine-type peptidase activity 4E-03 12
Serine hydrolase activity 4E-03 12
Phosphatase activity 5E-03 12
Actin binding 1E-02 11
Protein dimerization activity 1E-02 13
DNA binding 1E-02 37
Cation binding 1E-02 61
Cysteine-type endopeptidase activity 1E-02 4
Phosphoric ester hydrolase activity 1E-02 13
DNA-binding transcription factor activity 1E-02 16
Metal ion binding 1E-02 60
N-acetyl-beta-D-galactosaminidase activity 1E-02 2
Transcription regulator activity 3E-02 18
Serine-type endopeptidase activity 3E-02 9
Cytoskeletal protein binding 4E-02 14
Chloride transmembrane transporter activity 4E-02 3
Protein binding 4E-02 93
KEGG Lysosome 2E-04 10
Protein processing in endoplasmic reticulum 9E-04 12
Amino sugar and nucleotide sugar metabolism 8E-03 6
Metabolic pathways 9E-03 36
Other glycan degradation 3E-02 3
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Supplementary Table 12:  Enriched GO processes of uniquely upregulated genes in the Malpighian
Tubules





Metabolic process 6E-60 708
Cellular metabolic process 7E-44 546
Peptide biosynthetic process 9E-43 118
Translation 4E-42 116
Organonitrogen compound biosynthetic process 4E-42 176
Peptide metabolic process 8E-42 120
Amide biosynthetic process 1E-41 119
Cellular amide metabolic process 2E-39 122
Cellular process 2E-38 704
Organic substance metabolic process 6E-38 567
Organonitrogen compound metabolic process 4E-37 359
Primary metabolic process 5E-35 538
Nitrogen compound metabolic process 5E-35 505
Cellular nitrogen compound metabolic process 1E-32 334
Cellular nitrogen compound biosynthetic process 4E-32 244
Biosynthetic process 5E-31 295
Organic substance biosynthetic process 4E-30 288
Cellular biosynthetic process 6E-30 284
Cellular protein metabolic process 5E-26 239
Cellular macromolecule metabolic process 2E-24 349
Gene expression 7E-24 241
Protein metabolic process 1E-23 274
Macromolecule metabolic process 2E-23 428
Macromolecule biosynthetic process 2E-21 214
Cellular macromolecule biosynthetic process 1E-20 210
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Oxidation-reduction process 3E-18 130
Small molecule metabolic process 4E-17 119
Generation of precursor metabolites and energy 4E-14 46
Purine nucleoside triphosphate metabolic process 7E-13 28




Cell part 6E-48 532
Intracellular 5E-59 518
Intracellular part 2E-63 492
Intracellular organelle 3E-42 388
Organelle 4E-41 388
Cytoplasm 1E-85 334
Membrane-bounded organelle 8E-24 289
Intracellular membrane-bounded organelle 4E-24 286
Protein-containing complex 2E-43 260
Cytoplasmic part 7E-67 249
Intracellular organelle part 5E-24 197
Organelle part 2E-23 197
Non-membrane-bounded organelle 8E-21 127
Intracellular non-membrane-bounded organelle 8E-21 127
Ribonucleoprotein complex 2E-44 108
Mitochondrion 1E-30 90
Ribosome 4E-38 78
Organelle membrane 8E-15 65
Mitochondrial part 4E-23 61
Mitochondrial envelope 1E-16 47
Organelle envelope 4E-13 47
Envelope 6E-13 47
Mitochondrial membrane 1E-16 44
Mitochondrial inner membrane 9E-15 36
Organelle inner membrane 3E-14 36
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Mitochondrial protein complex 1E-10 25
Ribosomal subunit 2E-13 21
Proton-transporting two-sector ATPase complex 3E-12 20
Small ribosomal subunit 9E-11 14
Molecular
Function
Catalytic activity 2E-43 576
Structural constituent of ribosome 1E-39 80
Binding 6E-34 825
Heterocyclic compound binding 6E-29 467
Organic cyclic compound binding 7E-29 467
Ion binding 6E-27 405
Structural molecule activity 3E-24 90
Small molecule binding 2E-21 247
Anion binding 2E-21 243
Nucleotide binding 5E-20 231
Nucleoside phosphate binding 5E-20 231
Ribonucleotide binding 4E-18 205
Purine nucleotide binding 1E-17 203
Purine ribonucleotide binding 1E-17 202
Purine ribonucleoside triphosphate binding 2E-17 200
Carbohydrate derivative binding 3E-17 214
Oxidoreductase activity 2E-16 119
RNA binding 1E-15 103
Drug binding 1E-12 176
Adenyl nucleotide binding 1E-11 158
ATP binding 1E-11 156
Adenyl ribonucleotide binding 1E-11 157
Proton transmembrane transporter activity 2E-10 23
Hydrolase activity 8E-10 211
Transferase activity 2E-08 171
Translation factor activity, RNA binding 3E-08 22
Metal ion binding 7E-08 186
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Hydrolase activity, acting on acid anhydrides 7E-08 88
Pyrophosphatase activity 8E-08 87
Nucleoside-triphosphatase activity 8E-08 85
KEGG Metabolic pathways 2E-43 186
Ribosome 5E-36 68
Oxidative phosphorylation 6E-26 50
Proteasome 8E-13 22
Carbon metabolism 1E-10 29
Ribosome biogenesis in eukaryotes 2E-08 23
Phagosome 3E-08 22
Valine, leucine and isoleucine degradation 3E-08 15
Cysteine and methionine metabolism 8E-07 14
Protein processing in endoplasmic reticulum 2E-06 27
Glutathione metabolism 6E-06 13
Citrate cycle (TCA cycle) 3E-05 12
RNA transport 1E-04 25
Biosynthesis of amino acids 3E-04 14
Protein export 3E-04 9
Drug metabolism 4E-04 7
2-Oxocarboxylic acid metabolism 4E-04 7
Metabolism of xenobiotics by cytochrome P450 9E-04 7
Peroxisome 3E-03 13
Pyruvate metabolism 4E-03 7
Drug metabolism 4E-03 8
Glyoxylate and dicarboxylate metabolism 6E-03 7
Propanoate metabolism 6E-03 7
Glycolysis / Gluconeogenesis 7E-03 9
Fatty acid metabolism 1E-02 9
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MTOR signaling pathway 1E-02 14
Porphyrin and chlorophyll metabolism 1E-02 7
ABC transporters 1E-02 5
Pentose phosphate pathway 2E-02 6
Fructose and mannose metabolism 2E-02 5
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Supplementary Table 13:  Enriched GO processes of uniquely upregulated genes in the Brain





Cellular process 2E-41 914
Metabolic process 1E-23 763
Organic substance metabolic process 4E-25 672
Primary metabolic process 4E-25 647
Cellular metabolic process 1E-28 636
Nitrogen compound metabolic process 6E-24 598
Macromolecule metabolic process 4E-25 553
Cellular macromolecule metabolic process 3E-24 440
Cellular nitrogen compound metabolic process 1E-19 374
Biological regulation 3E-13 366
Organic cyclic compound metabolic process 3E-24 350
Heterocycle metabolic process 3E-24 347
Cellular aromatic compound metabolic process 7E-24 345
Regulation of biological process 1E-12 343
Nucleobase-containing compound metabolic process 4E-24 337
Regulation of cellular process 7E-13 334
Nucleic acid metabolic process 6E-27 309
Gene expression 1E-14 270
RNA metabolic process 1E-20 251
Response to stimulus 1E-11 241
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Cellular response to stimulus 3E-11 229
Macromolecule biosynthetic process 1E-09 225
Cellular macromolecule biosynthetic process 9E-10 223
Macromolecule modification 1E-13 207
Protein modification process 1E-12 187
Cellular protein modification process 1E-12 187
Cellular component organization or biogenesis 4E-12 158
Cellular component organization 8E-12 147
Response to stress 3E-10 69




Cell part 2E-35 629
Intracellular 1E-36 582
Intracellular part 4E-32 521
Organelle 2E-30 451
Intracellular organelle 1E-29 445
Membrane-bounded organelle 6E-31 385
Intracellular membrane-bounded organelle 3E-29 374
Nucleus 4E-27 282
Protein-containing complex 2E-14 239
Organelle part 1E-20 236
Intracellular organelle part 5E-20 232
Cytoplasm 2E-05 203
Nuclear part 7E-16 104
Catalytic complex 8E-11 85
Membrane-enclosed lumen 1E-08 70
Organelle lumen 1E-08 70
Intracellular organelle lumen 1E-08 70
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Nuclear lumen 5E-10 64
Endomembrane system 5E-05 63
Transferase complex 7E-10 51
Nucleoplasm 5E-08 45
Nucleoplasm part 4E-07 42
Chromosome 2E-05 36
Microtubule cytoskeleton 6E-04 32
Transferase complex, transferring phosphorus-containing
groups
2E-05 20
DNA-directed RNA polymerase complex 2E-06 18
RNA polymerase complex 2E-06 18
Nuclear DNA-directed RNA polymerase complex 2E-06 18




Organic cyclic compound binding 1E-28 592
Heterocyclic compound binding 1E-28 592
Protein binding 7E-27 476
Ion binding 3E-22 495
Nucleic acid binding 1E-18 349
Catalytic activity 9E-17 622
Purine nucleotide binding 3E-15 246
Ribonucleotide binding 3E-15 247
Purine ribonucleotide binding 3E-15 245
Nucleotide binding 4E-15 272
Nucleoside phosphate binding 4E-15 272
Purine ribonucleoside triphosphate binding 4E-15 242
Small molecule binding 7E-15 285
Anion binding 7E-15 280
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Carbohydrate derivative binding 6E-13 253
Transferase activity 6E-11 229
Adenyl nucleotide binding 2E-09 190
Adenyl ribonucleotide binding 3E-09 189
ATP binding 5E-09 186
DNA binding 7E-09 147
Metal ion binding 4E-08 240
Ribonucleoside binding 4E-08 59
Nucleoside binding 5E-08 59
Cation binding 5E-08 241
Purine nucleoside binding 9E-08 57
GTP binding 9E-08 57
Purine ribonucleoside binding 9E-08 57
Guanyl ribonucleotide binding 1E-07 57
Guanyl nucleotide binding 2E-07 57
KEGG Spliceosome 7E-09 37
Longevity regulating pathway 5E-04 13
RNA polymerase 4E-03 11
Basal transcription factors 4E-03 12
Endocytosis 4E-03 24
MAPK signaling pathway 4E-03 17
Glycerophospholipid metabolism 5E-03 13
RNA degradation 6E-03 16
Metabolic pathways 9E-03 113
Fanconi anemia pathway 9E-03 7
MTOR signaling pathway 9E-03 18
Notch signaling pathway 9E-03 8
Wnt signaling pathway 2E-02 15
Purine metabolism 4E-02 13
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Supplementary Table 14:   List of Enriched Biological Processes in common between the Brain (B),
Malpighian Tubules (MT) , and Ventriculus (V) of uniquely upregulated genes.









Nitrogen compound metabolic process
MT V
2




Regulation of biological process
Macromolecule modification
Biological regulation
Regulation of cellular process
B MT
5
Cellular nitrogen compound metabolic process
Gene expression
Cellular macromolecule metabolic process
Macromolecule biosynthetic process












Generation of precursor metabolites and energy
Organonitrogen compound biosynthetic process
Organic substance biosynthetic process
Purine ribonucleoside triphosphate metabolic process
Purine nucleoside triphosphate metabolic process
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Cellular amide metabolic process









Nucleic acid metabolic process
Heterocycle metabolic process
Cellular protein modification process
Organic cyclic compound metabolic process





Cellular component organization or biogenesis
Nucleobase-containing compound metabolic process
Cellular response to DNA damage stimulus
Cellular response to stimulus
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Supplementary Table 15:   List of Enriched Cellular Compartments  in common between the Brain (B),
Malpighian Tubules (MT), and Ventriculus (V) of Uniquely upregulated genes.




























Intrinsic component of membrane














































Nuclear DNA-directed RNA polymerase complex
Organelle lumen
Nuclear lumen
DNA-directed RNA polymerase complex




Supplementary Table 16:   List of Enriched Molecular Functions in common between the Brain (B),
Malpighian Tubules (MT), and Ventriculus (V) of Uniquely upregulated genes.
























Organic cyclic compound binding
Small molecule binding










Peptidase activity, acting on L-amino acid peptides




Chloride transmembrane transporter activity





















Structural constituent of ribosome
Hydrolase activity, acting on acid anhydrides
Proton transmembrane transporter activity














Supplementary Table 17:   List of Enriched KEGG in common between the Brain (B), Malpighian
Tubules (MT), and Ventriculus (V) of Uniquely upregulated genes.
Organs Total KEGG
B MT V 1 Metabolic pathways
MT V 1 Protein processing in endoplasmic reticulum
B MT 1 MTOR signaling pathway
V
3





Porphyrin and chlorophyll metabolism
Drug metabolism
Glyoxylate and dicarboxylate metabolism
2-Oxocarboxylic acid metabolism
Fructose and mannose metabolism
Pyruvate metabolism
Citrate cycle (TCA cycle)
Oxidative phosphorylation




Biosynthesis of amino acids




Valine, leucine and isoleucine degradation
Ribosome
Phagosome
Cysteine and methionine metabolism
Pentose phosphate pathway
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Carbon metabolism
Protein export
Propanoate metabolism
Fatty acid metabolism
B
12
Wnt signaling pathway
RNA polymerase
Glycerophospholipid metabolism
RNA degradation
Purine metabolism
Spliceosome
Endocytosis
Basal transcription factors
Longevity regulating pathway
MAPK signaling pathway
Notch signaling pathway
Fanconi anemia pathway
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